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INTRODUCTION 
 
 
 
1. General principles of transmembrane signalling 
 
 
The B-cell represents one of the two major types of lymphocytes in the immune system, 
responsible for the humoral immune response. The antigen receptor on B-cells is a cell-
surface immunoglobulin. After encountering the antigen B-cells differentiate into cells 
producing antibody molecules of the same antigen-specificity as their receptor.  
B-cells communicate with the environment through a variety of cell-surface receptors that 
recognize and bind molecules present in the extracellular environment. Beside the antigen 
receptor, which is the most important in the response to antigens, a variety of other surface 
molecules contribute to coordinate growth, differentiation, metabolism and survival of the B-
lymphocyte. These receptors convert extracellular ligand binding into an intracellular signal 
and activate intracellular pathways, which transmit the signal. This process is known as 
signal transduction. The final destination of receptor signalling is the nucleus, where the 
activation of transcription factors modifies gene expression. 
Cell-surface receptors are transmembrane proteins that undergo conformational changes after 
ligand binding. This change can enable them for instance to associate with and activate a 
trimeric G protein (G protein-coupled receptor) or a protein-tyrosine kinase (tyrosine kinase 
linked receptors), or to activate their own intrinsic protein kinase activity (receptor tyrosine 
kinases). The cytosolic signal may activate a cascade of protein kinases or act through 
increasing the concentration of intracellular signalling molecules named second messengers 
(cAMP, cGMP, small lipid molecules and Ca2+). These signal transduction pathways do not 
only transmit the signal, but also provide means for its amplification. Another important 
feature of signal transduction pathways is that they both converge- several receptors can 
activate the same signalling cascade or transcription factor- and diverge- one receptor or 
given transduction protein can have more than one effector. This provides means for specific, 
fine–tuned or complex responses to a variety of stimuli. 
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In B-cell signalling, tyrosine phosphorylation of membrane receptors is an important way to 
activate receptors. Amino acid motifs called ITAMs (immunoreceptor tyrosine based 
activation motifs) or ITIMs (immunoreceptor tyrosine based inhibitory motifs) are found in 
the cytoplasmic tails of Fc receptors, accessory chains of the B-cell receptor and other 
receptors. Phosphorylated tyrosine residues recruit intracellular signalling molecules to an 
activated receptor by binding a protein domain known as SH2 domain (Src homology 
domain 2). SH2 domains are phosphotyrosine binding motifs implicated in the regulation of 
protein-protein interactions and are thought to function as molecular adhesives facilitating 
the formation of protein complexes. SH2 domain binding to specific phosphotyrosine 
containing sequences may transmit intracellular signals by inducing conformational changes 
that alter an enzyme's catalytic activity or by altering the subcellular localization of a protein. 
Another protein domain involved in protein-protein interactions is the SH3 domain (Src 
homology domain 3), which binds proline-rich regions in diverse proteins to recruit them to 
signalling pathways. These binding domains can be found alone or in various combinations 
in proteins containing catalytic domains. These combinations provide great potential for 
complex interplay and cross-talk between different signalling pathways. 
 
1.1 The Ras / MAPK pathway 
 
The Ras/MAPK pathway is one of the best characterized pathway initiated by receptor 
tyrosine kinases. Ras is a small monomeric G protein with a central role in cell growth. In the 
active state it is bound to GTP while in the inactive state it is bound to GDP. Ras possesses 
an intrinsic GTPase activity that renders it inactive. In mammalian cells SOS, a guanine 
nucleotide exchange factor, controls the conversion of Ras from the normal, inactive state to 
the active state. SOS is brought to the membrane and activated by Grb2, an adaptor protein, 
in response to the phosphorylation of the receptor. Ras activates Raf, a serine/threonine 
kinase, which in turn activates MEK. In the MAP kinase pathway, this enzyme provides a 
convergence point, as it can be also activated by signals coming from G protein-coupled 
receptors. MEK is an enzyme with dual specificity, which can phosphorylate both threonine 
and tyrosine. Its target is Erk MAP kinase, which than activates target transcription factors 
directly into the cytoplasm or after its translocation to the nucleus. In the B-cell, MAP kinase 
pathways from the B-cell receptor or co-receptor combine to regulate the expression of many 
genes involved in cell growth [92,93]. 
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1.2 Second messengers 
 
Cyclic AMP is a classic second messenger. The initial step in the pathway is the activation of 
adenylate cyclase at the plasma membrane by an activated G protein associated with the 
receptor. cAMP binds to the regulatory subunit of PKA (protein kinase A) and releases the 
catalytic subunit of this enzyme, which is than free to translocate to the nucleus or to 
phosphorylate targets in the cytosol. One of the major substrates for PKA is CREB (cAMP 
response element binding protein). Phosphorylated CREB binds to CRE elements in the 
promoter of genes that are sensible to cAMP [94].  
The inositol-lipid pathway is a common pathway for many types of receptors and involves 
second messengers derived from phosphatidylinositol. The enzyme phospholipase C-γ can be 
recruited through a SH-2 domain to the site of receptor-associated tyrosine kinase activity at 
the cell membrane. Phosphorylation of a tyrosine residue in PLC-γ activates the enzyme, 
which then cleaves the membrane phosphatidylinositol biphosphate (PIP2) into inositol 
triphosphate (IP3) and diacylglycerol (DAG). Diffusion of IP3 away from the membrane 
causes the release of Ca2+ from intracellular storage sites into the cytosol, raising the 
intracellular Ca2+ level several times. The signal is sustained by the opening of Ca2+ channels 
into the plasma membrane. Ca2+ binds and activates a small cytosolic enzyme called 
calmodulin, which in turn binds to and regulates other enzymes or transcription factors like 
NF-AT. The signal eventually reaches the nucleus. DAG remains associated to the inner 
surface of the plasma membrane where it activates protein kinase C. Increased Ca2+ levels 
further activate this enzyme, which also initiate pathways leading to the nucleus [92,94]. 
 
1.3 Transcription factors with an important role in B-cell signalling 
 
1.3.1 The JAK-STAT pathway 
In contrast to signal transduction pathways that use a large number of components, like the 
MAPK and the inositol-lipid pathways, JAK-STAT pathway is much simpler. It is often 
activated by cytokine receptors that do not possess tyrosine activity. Binding of the ligand 
causes the receptor to dimerize and associate with and activate a JAK kinase. These are 
tyrosine kinases that phosphorylate transcription factors named STATs (signal transducer 
and activator of transcription). There are several JAK kinases and more than 7 STATs. Each 
STAT is phosphorylated by a particular set of JAK kinases. STAT phosphorylation leads to 
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the formation of homo- and heterodimers, which translocate to the nucleus and bind specific 
recognition elements in target genes. The activation of STATs is transient and can be 
terminated by the action of a phosphatase. STATs play important roles in numerous cellular 
processes including immune responses, cell growth and differentiation, cell survival and 
apoptosis [92,94].  
 
1.3.2 The NF-kB family of transcription factors 
The NF-kB transcription factors are important for B-cell activation. NFkB exists in the 
cytoplasm mainly as homo- or heterodimers with a family of structurally related proteins, 
called the Rel or Rel/NF-kB proteins. In non-stimulated cells, NF-kB complexes are 
sequestered in the cytoplasm in an inactive form via interaction with an inhibitory protein 
called IkB, which itself belongs to a structurally- and functionally-related family of proteins. 
When cells are stimulated by a variety of stimuli, like lipopolysaccharide (LPS) or CD40L, a 
kinase cascade leads to the phophorylation of two kinases, named Ikkα and Ikkβ, which form 
a dimer that in turn phosphorylates IkB. When phosphorylated, IkB dissociates from the 
complex and is rapidly degraded by proteosomes. NF-kB migrates to the nucleus where it is 
involved in regulating many aspects of the immune cell function, like cell survival, 
processing and presentation of antigen, responses to antigen recognition, aspects of the 
inflammatory response as well as responses against bacterial and viral infections [51]. The 
NF-kB transcription factor family consists of heterodimers or homodimers of the subunits 
NF-kB1 (p50), NF-kB2 (p52), c-REL, RELA (p65) and RELB. Different pairs of these 
subunits function at different stages of B cell development [57]. 
 
 
2. Pax-5 - the B-cell-specific activator protein 
 
 
BSAP/Pax-5 is a member of the Pax (paired box) family of transcription factors, which 
constitute a small group of conserved developmental control genes. BSAP (B-cell-specific 
activator protein) was identified as the mammalian homologue of a sea urchin protein 
(TSAP), which is involved in the developmental regulation of two pairs of nonallelic histones 
H2A-2 and H2B-2 [3]. It is the only member of the family that is expressed in B-
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lymphocytes. The other nine members of the Pax family identified so far have been 
associated with mouse developmental mutants and human syndromes. Deletion of the paired 
domain of Pax-3 is associated with the Splotch mutation in mice, characterized by spina 
bifida and exencephaly and with the Waardenburg's syndrome in humans, an autosomal 
dominant combination of deafness and pigmentary disturbances [20,80]; mutations in the 
Pax-6 gene are associated with congenital aniridia (lack of iris) in humans and the small eye 
(Sey) phenotype in mice- a semidominant mutation that in the homozygous condition results 
in the complete lack of eyes and nasal primordial [29]. 
 
2.1 Expression pattern 
 
BSAP is encoded by the pax-5 gene and is expressed at all stages of B-cell development 
except in terminally differentiated plasma cells [3]. In addition to all B-lymphoid organs, 
Pax-5 can also be found in the developing midbrain and adult testis of the mouse [1]. In 
accordance to this expression pattern, gene inactivation in the mouse germline revealed that 
Pax-5 plays an important role in B-lymphopoiesis and midbrain development. [84]. 
 
2.2 Molecular structure and DNA binding site 
 
All members of the Pax protein family have a C-terminal transactivation domain and a N-
terminal paired domain (the DNA binding domain). The transactivation domain is located in 
the 55 C-terminal amino acids of the molecule and contains a distinct 
serine/threonine/proline-rich sequence. This domain exerts its activating function from a 
promoter as well as an enhancer position and is subject of a strong negative regulation by 
adjacent sequences from the extreme C-terminus [16]. 
The paired domain consists of a stretch of 128 amino acids that has been well conserved in 
evolution and shows no obvious resemblance to other known DNA-binding motifs. Detailed 
mutational analysis of Pax-5 revealed the bipartite structure of a paired domain and lead to 
the identification of a nonpalindromic consensus recognition sequence [12]. 
In the model for the paired domain-DNA interaction (Fig. 1) the paired domain binds to its 
recognition sequence from one side of the DNA helix and interacts with two successive 
major grooves. The Pax-5 recognition sequence is divided in two halves, each corresponding 
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A GA     GG
G . .  CA .  TG . . GCGTGACCA
PAX-5 PAIRED DOMAINC N
PAX-5 CONSENSUS SEQUENCE
Fig.1 Model of the paired domain-DNA interaction. The amino- and carboxi-terminal regions 
of the paired domain contact two successive major grooves from the same side of the DNA helix. 
 
 
 
to one major groove contact site. The amino-terminal subdomain recognizes the more 
extensive 3’ consensus motif of the Pax-5 binding site, whereas the carboxy-terminal part 
interacts with the 5’ consensus motif. 
One important observation of this model is that sites with a complete match to the consensus 
motif possess a very high affinity for Pax-5, which apparently is not required in vivo. All 
naturally occuring binding sites identified so far deviate from the consensus sequence and 
Pax-5 is able to interact with a panel of degenerate recognition sequences [12]. 
 
2.3 Role of Pax-5 in B-cell lineage commitment 
 
Pax-5 is an essential B lineage commitment factor. Normal expression of E2A and EBF, two 
transcription factors implicated in the myeloid versus lymphoid lineage decision and located 
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upstream of Pax-5 in the B-cell developmental process, is not sufficient to commit B-cell 
progenitors to the B-lymphoid lineage in the absence of Pax-5. In Pax-5-/- mice B-cell 
development is arrested at early pro-B-cell stage in the bone marrow. These Pax-5-/- pro-B-
cells still retain a broad lymphomyeloid development potential characteristic of uncommited 
hematopoiectic progenitors [60,67]. Upon appropriate cytokine stimulation, Pax-5-/- pro-B-
cells are able to differentiate in vitro into functional NK cells, dendritic cells, macrophages, 
osteoclasts and granulocytes [60]. In addition, Pax-5-/- pro-B-cells possess extensive in vivo 
self-renewal potential and long-term reconstitution potential, which are features of 
hematopoietic stem cells (HSC), yet they fail to reconstitute the hematopoietic system of 
lethally irradiated mice [72]. 
Binding sites for Pax-5 have been identified in promoters of several genes. While activating 
CD19, mb-1, RAG-2 and BLNK [43,59,39] Pax-5 acts as a repressor for the XBP-1, the M-
CSF-R, the immunoglobulin heavy-chain 3’C∝ enhancer and the J-chain gene [64,66,75].  
The conversion to a repressor function appears to be possible by recruitment of corepressors 
of the Groucho family to selected target genes [19]. 
At lineage commitment, Pax-5 has a dual role by repressing “lineage-inappropriate” genes 
and simultaneously activating B-cell-specific genes, which leads to the consolidation of the 
B-lymphoid gene expression program. This role is best illustrated by the regulation of M-
CSF-R and BLNK genes. By repressing M-CSF-R gene, Pax-5 renders B-cell precursors 
unresponsive to M-CSF, and prevents them to differentiate to monocytes under the influence 
of this cytokine. On the other hand, by activating the BLNK promoter, Pax-5 enables the 
expression of a central adaptor protein in BCR signaling [73]. 
 
2.4 Role of Pax-5 in late B-cell development 
 
Pax-5 functions also at later stages of B cell development. The generation of a mouse strain 
in which the Pax-5 gene can be conditionally inactivated enabled the analysis of Pax-5 
function in mature B cells [31]. Loss of Pax-5 resulted in a change of B cell subpopulations 
in the periphery with downregulation of several mature cell surface B cell markers. 
Considering that Pax-5 is also repressing XBP-1, a transcription factor essential for plasma-
cell differentiation, it proves its important role for maintaining the identity and function of 
mature B cells.  
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Furthermore, Pax-5 might play a role in isotype class switching by regulating germline 
transcription from the downstream constant region gene, which appears to be a prerequisite 
for subsequent class switching. IgH gene expression and rearrangement are regulated by 
multiple cis-acting elements within the IgH locus, including the intronic enhancer (Eµ), the I 
regions of the constant region genes and the complex regulatory region 3’ of Cα. Pax-5 was 
reported to bind at multiple sites in the IgH gene cluster, including regions located upstream 
of switch regions, like Sγ2a [46] and Sµ [86] and at sites within the 3’ control region [52]. 
Repression or activation of these regulatory sites appears to require a concerted effort 
involving additional factors, such as octamer binding proteins and NF-kB-like complexes. 
 
 
3. CD23- the low affinity receptor for IgE 
 
 
CD23 was described as a low-affinity receptor for IgE (FcεRII) expressed on mature 
peripheric B-cells. The same molecule, expressed at high levels on Epstein-Barr virus-
transformed cells was independently described as a B-cell activation marker. 
The CD23 molecule is a type II membrane glycoprotein exhibiting substantial homology 
with several Ca2+-dependent animal lectins. In humans it is expressed in two isoforms 
(CD23a and CD23b). CD23 has a functional role as a transmembrane receptor as well as a 
soluble receptor derived from the cell-bound form. CD23 is an important player in allergic, 
autoimmune and lymphoproliferative diseases. 
In humans, the expression of CD23 is increased in allergic disorders, in terms of membrane 
expression on B-cells and monocytes but also in terms of sCD23 production [24]. The 
number of circulating CD23-bearing B-cells is also increased in patients with rheumatoid 
arthritis. In type II collagen-induced arthritis in mice, a model for human rheumatoid 
arthritis, antibody neutralisation of CD23 significantly ameliorated the disease, proving the 
involvement of the molecule in inflammatory processes [63]. In B-CLL patients, high levels 
of sCD23 in the serum are correlated with the clinical stage of the disease and can be used as 
prognostic marker. The accumulation of sCD23 results from an increased number of CD23-
bearing B-cells but also from the overexpression of CD23 on the surface of malignant cells 
[69]. 
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3.1 Cellular expression and its regulation 
 
On normal human B-cells CD23 expression is restricted to mature peripheric B-cells co-
expressing IgM and IgD. After switching to IgG, IgA and IgE B-lymphocytes cannot be 
induced to reexpress CD23. The receptor is comparably expressed on CD5+ and CD5- 
circulating or tonsilar B-cells. 
CD23 is also found on T-cells, monocytes, macrophages, platelets, eosinophils, Langerhans 
cells and follicular dendritic cells [13]. 
Normal human B-lymphocytes from peripheral blood express both CD23 antigen and CD23 
mRNA. Still the molecule is not constitutively expressed since after 48 hours of incubation in 
the absence of a stimulant, highly purified B-cells loose both CD23 antigen and CD23 
mRNA.  
The major inducer of CD23 on B-cells is IL-4, which triggers the expression of both 
isoforms. The peak effect is observed after 36-48 hours. Signals delivered via CD40 
synergize with IL-4 for the induction of CD23 on mature peripheral B-cells and interactions 
between B and T cells (presumably dependent on CD40) result in upregulation of CD23. 
EBV-transformation of B-cells leads to CD23 expression, which plays a role in the 
immortalization of the cell [8]. 
IFN-γ and IFN-α inhibit IL-4 induced expression of CD23 on normal B-cells at the protein 
and mRNA level [15]. 
IL-4 is also the main CD23 inducer on all the other CD23 bearing cell types. 
 
3.2 Structure of the molecule 
 
Human CD23 is a 45 kDa glycoprotein member of the C-type animal lectin family, with a 
long C-terminal extracellular domain, a short cytoplasmic N-terminus and is anchored by a 
single transmembrane region [13]. 
The extracellular part of the molecule consists of three regions (Fig. 2):  
- the leucine zipper sequence near the transmembrane domain has a seven-amino-acid 
motif beginning with Leu or Ile that is repeated five times in the case of human CD23 
and forms an α-helical coiled coil stalk region [5]. This region mediates the formation 
of trimers; 
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Fig. 2 Schematic representation of the CD23 receptor 
 
 
- the lectin head, a motif which mediates the binding of carbohydrates in a Ca2+ dependent 
manner. It consists of four highly conserved and two partially conserved  
cystein residues which interact by disulphide bonds and contains Ca2+ and sugar –binding      
amino acids; 
- the inverse RGD sequence, a common recognition site for integrins, is located near the C-
terminus of the molecule. 
The intracytoplasmic part is very short, containing only 21-22 amino acids for Cd23a and 
CD23b respectively. 
The membrane form gives rise to soluble fragments by an autocatalytic process involving a 
matrix metalloprotease. Cleavage at different sites gives rise to fragments of 37, 33, 29, 25 
and 17 kDa, all retaining the binding capacity to IgE, although the smaller fragments with 
lower affinities. Soluble forms bigger than 25kDa upregulate IgE production.  
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Binding of IgE and IgE-IC protects and stabilizes the stalk from proteolyses in this way 
inhibiting the release of soluble fragments from the membrane form. 
 
3.3 Ligands for CD23 
 
The first ligand to be described for CD23 was IgE. Although IgE is highly glycosilated, the 
lectin homology region of CD23 appears to bind the protein moiety of the molecule, 
independently of carbohydrates. However, the binding is Ca2+ dependent and the correct 
folding of the lectin domain is critical, since deletion of conserved cysteins has a deletorious 
effect on IgE binding [6]. The CD23-binding site was mapped in the Cε3 constant region 
domain of IgE, in close proximity of the high-affinity receptor (FcεRI) binding site. The 
oligomerization of CD23 is an important factor in enabling high affinity binding to IgE. 
The other ligands described for CD23 are CD21 (CR2), CD11b/CD18 (CR3) and 
CD11c/CD18 (CR4) - two members of the LFA-1 family. 
Fucose-1-phosphate has been described as a competitive inhibitor of both IgE and CD21 
binding for CD23 [26]. 
 
3.4 Biologic activity 
 
Membrane CD23 and its soluble forms have been implicated in different functions, ranging 
from cellular adhesion, antigen presentation, growth and differentiation of B and T cells, 
rescue from apoptosis, release of cytotoxic mediators and regulation of IgE synthesis. 
A well-characterized function of membrane-bound CD23 in B-cells is the enhancement of 
IgE-dependent antigen presentation to T-cells [23,27,35]. This requires the binding of 
antigen-IgE immune complexes to CD23, internalization of the complexes and transport to 
compartements of the endosomal network containing proteolytic enzymes and major 
histocompatibility complex class II antigens. CD23 is spatially associated with MHC class II 
DR on B-cells [34]. 
CD23 functions also as an adhesion molecule. Antigen presentation involves interaction 
between CD23 and CD21 at points of contact between B and T cells [2,7]. 
Human CD23 plays also a regulatory role in the IgE production with positive and negative 
effects. Crosslinking CD23 at the cell surface by IgE inhibits the release of sCD23 and 
delivers a negative feedback for IgE production. In contrast, sCD23 fragments larger than 25 
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kDa that retain part of the stalk region promote IgE production. Two possible mechanisms 
are discussed: (1) sCD23 possibly stimulates IgE production through CD21 triggering; (2) 
sCD23 traps IgE in the medium and prevents the negative feedback through membrane-
bound CD23 [83]. 
There is evidence that soluble CD23 fragments exert other important roles except the 
regulation of IgE synthesis. In synergy with IL-1, sCD23 acts as a differentiating factor for 
early thymocytes [55] and induces proliferation of human bone marrow derived myeloid 
precursors [56]. It is also involved in the rescue of germinal center B-cells. In the presence of 
recombinant 25 kDa sCD23 and IL-1α centrocytes are rescued from apoptosis and can 
differentiate into plasmocytoid cells [49]. This is supported by the high density of CD23 on 
the surface of follicular dendritic cells in the light zone of the germinal center. 
On monocytes, eosinophils and platelets, CD23 is involved in IgE dependent cytotoxicity 
against some parasites and in the IgE induced release of different mediators of inflammation 
[10,17]. CD23 also mediates the phagocytosis of IgE coated particles. Finally, sCD23 
ligation of CD11b/CD11c on monocytes is able to promote release of inflammatory 
mediators such as IL-1β, IL-6 and TNF [45]. 
 
3.5 Isoforms of human CD23 
 
Two isoforms of human CD23 (CD23a and CD23b) have been described. They differ by 
only 6-7 residues in the extremity of the cytoplasmic tail. CD23a contains a unique tyrosine 
residue while CD23b does not. CD23a is restrictively expressed on B-cells and EBV-
transformed B-cell lines while CD23b is inducible on B-cells, as well as monocytes, 
eosinophils, macrophages and a variety of other cell types [87]. 
The two isoforms seem to be correlated to different functions associated with CD23. CD23a 
appears to be the isoform associated with endocytosis of IgE IC and mediating Ag 
presentation on B-cells. Yokota et al. identified a five amino-acids sequence in which the 
first residue is aromatic (Tyr-Ser-Glu-Ile-Glu) and that is particularly critical for endocytosis 
of coated pits [88]. CD23b has a phagocytosis motif (asparagine and proline in positions 2 
and 3). Although the function of this isoform on B-cells is unclear, on myeloid cells it seems 
to be involved in the phagocytosis of IgE-coated particles, cytokine release and the 
generation of superoxides. There is solid circumstancial evidence that the two isoforms 
connect to different signalling transduction pathways. 
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CD23 expressing cells CD23a              CD23b
B cell + +
T cell - +
Follicular dendritic cells - +
Langerhans cells - +
Monocytes - +
Macrophages - +
Eosinophils - +
Platelets - +
Thymic epithelial cells - +
 
Fig.3 The two isoforms of human CD23 are differentially expressed on cells of the 
hematopoietic lineage. 
 
 
3.6 Genomic structure of the human CD23 gene and analyses of its transcriptional 
regulation 
 
CD23 is encoded within the human genome by a single gene located on chromosome 19. It 
consists of 11 exons, with a good correlation between the exon/intron structure and the 
corresponding domains of the protein. Exons 5-7 seem to have arisen by a triplication of an 
exon coding for an exact number of heptads and encode the stalk region. Exons 9-11, which 
are separated by a large intron from the rest of the gene, encode for the soluble forms of 
CD23. 
The two isoforms, which differ by six aminoacids at the cytoplasmic amino terminus, are 
generated by using different transcriptional start sites and alternative RNA splicing (Fig. 4). 
Given the genomic sequence of CD23a as a reference, CD23b mRNA is lacking the first two 
exons and starts with an optional exon that is located within intron II. The two mRNAs share  
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Fig.4 Genomic organization of the CD23 gene 
 
 
the part of the molecule incoded starting with exon 3- the extracellular, transmembrane and 
partially the intracellular domain [87]. 
The CD23a promoter sequence was first described by Suter et al. [79] and the CD23b 
promoter was identified by Yokota [87]. The first studies of the CD23a promoter identified a 
CCAAT motif, as well as four Alu sequences and repeat elements that form an extensive 
inverted repeat surrounding the promoter. Later studies of both promoters identified several 
transcription factors binding sites. 
Both CD23a and CD23b promoters contain canonical STAT6 binding sites (TTC-N4-GAA) 
and at least one of these elements is a defined IL-4 responsive element [21,41]. Similarly, 
sequences containing NF-kB binding sites (GGGRNNYYCC) are also found in both CD23a 
and CD23b upstream regions [40]. Binding sites for NF-AT transcription factors and 
candidate AP-1 binding sites (TGASTCA) have been characterized in the CD23b promoter 
[21,40]. 
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EBNA-2 targets the CD23a promoter through a DNA-binding protein, CBF-1, which binds a 
recognition sequence with the common core motif GTGGGAA [48,85]. EBNA-2 is a 
transcriptional activator that modulates Epstein-Barr virus latency gene expression as well as 
the expression of cellular genes. CD23 expression is upregulated by EBNA-2 along with 
CD21 [11]. Activation of CD23 might be particularly important, since only EBV-infected B-
cells expressing this marker become immortalized. Notch-2 also can regulate the CD23a 
promoter by binding to CBF1 sites. The Notch family genes encode transmembane receptors 
that modulate differentiation and proliferation. Notch-2 activation of the CD23a promoter 
through CBF1 responsive elements may play a role in the immortalisation of the cell and the 
pathogenesis of B-CLL [32].   
Emerging data seem to lead to the conclusion of differential regulation of the CD23a and 
CD23b promoters, with CD23a showing less sensitivity to external stimuli than the CD23b 
promoter, at least in B-cells [21]. This would be in agreement with the idea of the two 
isoforms having different functions. 
 
3.7  The murine CD23 receptor 
 
The mouse CD23 shares only 57% aminoacid sequence homology with the human molecule. 
The protein is lacking the RGD motif by a naturally occuring truncation and the sCD23 
fragments bind IgE with a much lower affinity [4]. There are also differences in the cellular 
distribution between species, with the mouse CD23 expressed only on B-cells, follicular 
dendritic cells and some T-cells. All these differences in structure and cellular expression 
may account for the differences in functions between mice and humans. From the study of 
CD23-/- mice, murine CD23 may not have the regulatory effects ascribed to human sCD23. 
CD23-/- mice display normal lymphocyte development, normal B-cell proliferation and 
germinal center formation. However, antigen-specific IgE-mediated enhancement of 
antibody responces was severely impaired, suggesting the role of murine CD23 in antigen-
presentation [23,27]. Regarding the role of mouse CD23 in IgE production, some studies did 
not find modifications of IgE levels in the serum of CD23-/- mice [23,77], while other studies 
of heterozygous and transgenic mice suggest that the murine CD23, in particular the 
membrane-bound form, exerts an inhibitory role on IgE production [81,89]. There are no 
expressed isoforms described yet and the mouse CD23 seems to be more related to the 
CD23a human isoform, by distribution and functions: the cytoplasmic tail of the mouse 
CD23 contains a Tyr residue, part of an YSGT sequence and the mouse promoter also 
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displays homologies to the CD23a promoter. IL-4 is also the main inducer of mouse CD23. 
STAT6 and NF-kB binding sites have been described [82]. 
 
3.8 Signal transduction through the CD23 receptor 
 
The intracellular signal transduction pathway activated through CD23 has been studied by 
Kolb and coworkers [42]. In human activated B-cells cross-linking of CD23 provokes a rapid 
increase in Ca2+, which results from the generation of inositol (1,4,5) tri-phosphate following 
phospholipase C-dependent hydrolysis of phosphatidylinositol (4,5)-biphosphate. It has been 
suggested that G protein couples membrane CD23 to a PLC and it is possible that a tyrosine 
kinase is also involved. Evidence was provided by an experiment in which the product of the 
transfected CD23 gene in a NK cell line was found associated with p59fyn -a member of the 
src family of protein kinases [78]. Cross-linking of CD23 on the surface of resting or IL-4 
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Fig.5 Schematic diagram of the CD23 receptor and known signal transduction pathways 
in murine and human B cells. 
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stimulated B-cells resulted in a slow accumulation of intracellular cAMP, although it was 
unclear to what extent increased Ca2+ levels were dependent upon the prior activation of 
PLC. However, since this change could be observed in resting B-cells, where neither Ca2+ 
mobilization nor inositol (1,4,5) tri-phosphate production are significantly altered on 
engaging CD23, suggests that the elevation in cAMP levels may proceed independently of 
PLC activation. Moreover, cAMP accumulation was observed in monocytes, where the 
phosphoinositide pathway is clearly not involved [26]. In human monocytes CD23 is 
additionally coupled with the activation of inducible nitric oxide synthase (iNOS) pathway 
[18]. 
This would indicate that the B-cell specific, CD23a isoform and the non-lineage restricted 
CD23b isoform have distinct signalling mechanisms. The divergence in the signalling 
pathways must relate to the first 6-7 aminoacids of their cytoplasmic N-termini.  
 
 
4. Two-hybrid systems 
 
 
Two-hybrid systems provide a powerful technique to screen large libraries of genes and to 
identify new protein-protein interactions within the cell. A certain number of yeast, bacterial 
and mammalian two-hybrid systems have been developed in the last years.  
 
4.1  CytoTrap Two Hybrid System 
 
The CytoTrap Two Hybrid System (Stratagene) is based on generating fusion proteins 
whose interaction in the yeast cytoplasm induces cell growth by activating the Ras signaling 
pathway. 
The yeast strain used by the system- called cdc25H- contains a point mutation in the cdc25 
gene, which is the homologue of the human SOS. The gene encodes a guanyl nucleotide 
exchange factor for Ras. The mutation prevents host growth at 37°C, with a permissive 
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temperature of 25°C. The system is based on the ability of the human SOS to complement 
the defect and activate the yeast Ras signalling pathway. 
DNA encoding the bait protein is cloned into a vector, which will express it as a fusion 
protein with human SOS. DNA encoding the library (target) is cloned in the pMyr vector. 
The genes of the cDNA library will be expressed as fusion proteins to the myristilation 
signal, which will anchor them to the membrane. If the bait and target physically interact, 
hSOS is recruted to the membrane, activating the Ras signalling pathway and allowing the 
yeast to grow at 37°C (Fig. 6). 
This system offers some advantages over the traditional two-hybrid systems: 
1. it provides a better control of the activation; 
2. it does not involve protein transport to the nucleus; 
3. it can be used for proteins which are transcriptional activators or repressors. 
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Fig.6 Schematic diagram of the Ras signalling pathway used in the CytoTrap Two Hybrid System 
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In order to express fusion proteins in the yeast cytoplasm, the system provides two 
expression vectors. 
The pSos vector (Fig. 18) contains the hSOS gene cloned upstream of the multiple cloning 
site and under the control of the ADH1 promoter which is constitutively active. It is 
designed with replication origins for propagation in yeast and bacterial strains and 
selectivity markers for transforming in yeasts (the auxotrophic marker LEU2) and bacteria 
(the ampicillin resistance gene). 
The pMyr vector (Fig. 18) contains the gene coding for the myristilation signal cloned 
upstream of the target gene and under the control of the GAL1 promoter, which is inducible 
by adding galactose into the medium. It is designed with replication origins for propagation 
in yeast and bacterial strains and selectivity markers for transforming in yeasts (the 
auxotrophic marker URA3) and bacteria (the chloramphenicol resistance gene).  
The different antibiotic resistance genes used by the two vectors allow to rapidly distinguish 
between the bait and the target vector when recovering plasmids from yeasts. 
As controls, four different expression vectors are provided by the system: pSosMAFB, 
pMyrMAFB, pSosColl and pMyrLamin C. pSosMAFB and pMyrMAFB express the SOS 
protein or the myristilation signal as fusion proteins with full-lengh MAFB, a transcription 
factor that can form homodimers via its leucine zipper domain. pSosColl expresses the SOS 
protein as a fusion protein with the murine 72 kDa type IV collagenase (aa 148-357) and 
pMyrLamin C expresses the myristilation signal as fusion a protein with human lamin C (aa 
67-230). These plasmids are used in pairwise combinations as positive and negative controls 
for the rescue of the temparature-sensitive phenotype of cdc25H. pSosMAFB and 
pMyrMAFB protein products interact in vivo. Co-transformation of these two control 
plasmids permits growth of the cdc25H mutants at the restrictive temperature of 37°C. The 
pSosMAFB + pMyrLamin C plasmid pair and the pSosColl + pMyrMAFB plasmid pair are 
negative controls whose protein products do not interact in vivo. These proteins do not allow 
the growth of cdc25H mutants at 37°C. 
 
4.2  MATCHMAKER GAL4 Two-Hybrid System 3  
 
This system (provided by Clontech) is a GAL4- based two-hybrid that provides a 
transcriptional assay for detecting protein interactions in vivo in yeasts. The bait gene is 
expressed as a fusion protein with the GAL4 DNA-binding domain (DNA-BD), while 
another gene or cDNA is expressed as a fusion protein to the GAL4 activation domain (AD).  
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Fig.7 Schematic diagram of the principle employed by the MATCHMAKER3 GAL4 
Two Hybrid System 
 
 
When bait and library fusion protein interact, the DNA-BD and AD are brought into 
proximity, thus activating transcription of four reporter genes: ADE2, HIS3, MEL1 and lacZ 
(Fig. 7). The system can be used to identify novel protein interaction as well as to confirm or 
define suspected interacting domains.  
The system uses four different reporter genes under the control of distinct GAL4 upstream 
activating sequences (UASs) and TATA boxes. ADE2 and HIS3 reporters allow strong 
nutritional selection and the control of the stringency of selection. MEL1 and lacZ, which 
incode for α-galactosidase and β-galactosidase respectively, allow the employment of 
blue/white screening.  
The vectors of the system- pGBKT7 and pGADT7 are designed to express different 
bacterial transformation markers- kanamycin and ampicillin, different yeast selection 
markers- -TRP1 and LEU2, c-Myc and hemagglutinin (HA) epitope tags for convenient 
identification of the fusion proteins and T7 promoters to allow in vitro transcription and 
translation of epitope-tagged fusion proteins. 
The positive controls of the system are pGBKT7-53 and pGADT7-T vectors, which incode 
fusion proteins between GAL-4 DNA-BD and AD and murine p53 and SV40 large T-
antigen. p53 and large T-antigen interact in a two-hybrid assay. Additionally, pCL1 encodes 
the full-length wild-type GAL4 protein and provides a positive control for α-galactosidase 
assays. 
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The negative control of the system is pGBKT7-Lam vector, which encodes for a fusion of 
the DNA-BD with human lamin C. This protein neither forms complexes nor interacts with 
most other proteins. 
The yeast strains provided by the system- AH109 and Y187 are gal4- and gal80- in order to 
prevent the interference of native regulatory proteins with the regulatory elements of the 
two-hybrid system. AH109 usage is recommended for library screens using HIS3, ADE2 
and MEL1. Y187 usage is recommended for testing interactions between two known 
proteins using the lacZ reporter only. 
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AIMS OF THE PROJECT 
 
 
 
Two isoforms of human CD23 (CD23a and CD23b) have been described. They differ by 
only 6-7 residues in the extremity of the cytoplasmic tail. CD23a is restrictively expressed on 
B-cells while CD23b is inducible on B-cells, as well as monocytes, eosinophils, 
macrophages and a variety of other cell types after IL-4 stimulation. 
The two isoforms seems to have different functions. CD23a appears to be the isoform 
associated with endocytosis of IgE IC and mediating antigen presentation on B-cells. CD23b 
has a phagocytosis motif and seems to be involved in the phagocytosis of IgE-coated 
particles, cytokine release and the generation of superoxides. 
Previous studies indicate that the two isoforms connect to different signalling transduction 
pathways. The comparison of events taking place in cells that express only one or both CD23 
isoforms would suggest that CD23b is involved in upregulating cAMP and iNOS, whereas 
CD23a mediates an increase in intracellular calcium. Additionally, recent observations show 
that there is distinct regulation of the two promoters. 
Two questions regarding the biology of the CD23 receptor were addressed in this study: 
1) How is the B-cell specific expression of CD23a isoform regulated? In particular, is the B-
cell specific activator protein BSAP/Pax-5 implicated in the control of CD23a expression? 
2) Who are the direct interaction partners of the two CD23 isoforms? In particular, can yeast 
two-hybrid systems be used in order to look for cytoplasmic interaction partners for the 
CD23 receptor? 
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 MATERIALS AND METHODS 
 
 
1.Gene cloning 
 
1.1 Plasmid constructs 
y The following plasmids were used for in vitro transcription:  
pBS-23A contains a 299 bp cDNA fragment of CD23a cloned into the SmaI site of the 
pBlueScriptSK+ vector (Stratagene). 
pBSβ−actin contains a 540 bp cDNA fragment cloned in the pBlueScriptSK+ vector 
(Stratagene). 
y The following plasmids were used for in vitro transcription and translation: 
pCR-Pax-5 –contains the full length human Pax-5 gene cloned in the MCS of the pCR-Zero 
Blunt vector (Invitrogen). 
y The following plasmids were used in mammalian cell transfections/reporter gene assays: 
pcDNA3-Pax-5 contains the human Pax-5 gene cloned in the EcoRI site of the pcDNA3 
vector (Stratagene). 
pEGZ –Pax-5 contains the human Pax-5 gene inserted between the EcoRI and SmiI sites of 
the pEGZ vector; pEGZ vector was provided by Dr. I. Berberich (Institute for Virology, 
Würzburg). 
pLuc+ACP and pLuc+AP contain the CD23a core promoter (-203 to +83) and the CD23a 
promoter (-1216 to +211) cloned in the SalI site of the pLuc+ vector; pLuc+ vector was 
provided by Dr. J. Altschmied and all the pLuc+ constructs have been previously made in our 
lab. 
pXM-STAT6 was kindly provided by Dr. E. Pfitzner (Frankfurt). 
y The following plasmids were used in two-hybrid systems: 
pSosCD23a and pSosCD23b contain the intracytoplasmic part of the CD23 isoforms cloned 
in the MCS of the pSos vector. The constructs have been previously made in our lab. 
pSosCD23a+Linker and pSosCD23b+Linker contain the intracytoplasmic part of the CD23 
isoforms and a linker region cloned in the HindIII site of the pSos vector, upstream of the 
human SOS gene. 
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pSosCD23a-Glu represents the construct pSosCD23a+Linker in which the tyrosine in 
position 6 of the cytoplasmic tail of CD23a has been replaced with a glutamic acid using site 
directed mutagenesis. 
pMyr-fyn contains the fyn gene cloned in the MCS of the pMyr vector. 
pGBKCD23a and pGBKCD23b contain the intracytoplasmic part of the CD23 isoforms 
cloned between the EcoRI and XhoI sites of the pGBK vector. 
pGAD1/12 constructs contain different clones (spleen library genes) transferred from the 
pMyr library and cloned between the NcoI and BamHI site of the pGAD vector. 
 
1.2 Oligonucleotides 
The following annealed oligonucleotides (MWG-Biotech) were cloned inside the MCS of 
the pSos vector: 
y CD23a –intracytoplasmic part 
M191- 5’-GGC CAA GCT TCC ACC ATG GAG GAA GGT CAA TAT TCA GAG ATC            
    GAG GAG CTT CCC AGG AGG CGG TGT TGC AGG CGT GGG GGA TCC CG-3’ 
M192- 5’-CGG GAT CCC CCA CGC CTG CAA CAC CGC CTC CTG GGA AGC TCC TCG  
    ATC TCT GAA TAT TGA CCT TCC TCC ATG GTG GAA GCT TGG CC-3’ 
y CD23b- intracytoplasmic part 
M193- 5’-GGC CAA GCT TCC ACC ATG AAT CCT CCA AGC CAG GAG ATC GAG GAG  
    CTT CCC AGG AGG CGG TGT TGC AGG CGT GGG GGA TCC CG-3’ 
M194- 5’-CGG GAT CCC CCA CGC CTG CAA CAC CGC CTC CTG GGA AGC TCC TCG  
    ATC TCC TGG CTT GGA GGA TTC ATG GTG GAA GCT TGG CC-3’ 
y Linker region 
M195-5’-CGG GAT CCG GCG GTG GCG GTT CTG GTG GCG GTG GCT CCG GCG GTG  
   GCG GTT CTG AAG CTT CGG G-3’ 
M196-5’-CCC GAA GCT TCA GAA CCG CCA CCG CCG GAG CCA CCG CCA CCA GAA  
   CCG CCA CCG CCG GAT CCC G-3’ 
 
1.3 Annealing reaction 
The standard reaction by which two complementary oligonucleotides were annealed in a 
double stranded DNA fragment was: 
2 nmol oligonucleotide 1 
2 nmol oligonucleotide 2 
H2O up to 50 µl 
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The reaction was incubated for 5 min at 95°C and left in a 100°C water bath to cool till it 
reached room temperature. 
 
1.4 RT-PCR 
The reaction was performed using Titan One Tube RT-PCR System (Roche) a sensitive 
technique that allows cloning of RNA messages in one step reaction. 
a. The following combinations of primers (Gibco) were used: 
Pax-5 Fwr   M130 - 5'-TTC CCT GTC CAT TCC ATC AA-3'  
Pax-5 Rev        M131- 5'-TCA TGG GCT CTC TGG CTA-3'  
CD23a Fwr 5’-GCCATGGAGGAAGGTCAATATTCA-3’  
CD23a Rev  5´-GACTTGAAGCTGCTCAGATCTGCT-3’   
β−actin Fwr  5'-GTGGGGCGCCCCAGGCACCA-3’ 
β−actin Rev  5’-CTCCTTAATGTCACGCACGATTTC-3’ 
p59 fyn Fwr    5’ –AGA GGA CCA TGT CAG TGG GCT- 3’ 
p59 fyn Rev    5’ –TCA CAT GCA ATC TGA TCC TGG- 3’ 
b. Reaction components (all reagents were provided by Roche, except RNase Inhibitor 
RNAguardTM, which was purchased from Amersham Pharmacia): 
Master Mix 1 (total of 25µl)    Master Mix 2 ( total of  25µl) 
1µl dNTP (10mM each)    10 µl 5xRT-PCR Buffer 
1µl downstream primer (10pmol/µl)   1 µl enzyme mix 
1µl upstream primer (10pmol/µl)   14 µl H2O 
1µl RNA template (1µg/µl) 
2.5 µl DDT (100mM) 
0.25 µl RNase Inhibitor (32 U/µl) 
18.25 µl H2O 
Master Mix 1 and Master Mix 2 were mixed gently.  
c. The conditions for the RT-PCR reaction were: 
1 cycle- elongation 30 min at 50°C 
denaturation  2 min at 94°C 
10 cycles - denaturation 15 sec at 94°C,  
annealing  30 sec at (*)°C 
elongation  (‡) sec, at 68°C  
25 cycles - denaturation  15 sec at 94°C,  
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annealing  30 sec at (*)°C 
elongation  (‡) sec at 68°C  + cycle elongation of 5 sec for each 
cycle 
1 cycle - elongation 7 min at 68°C  
 
Amplification product (*) Annealing temperature     (‡) Elongation time 
CD23a    61°C        45 sec 
Pax-5    66°C       60 sec 
β-actin    66°C       45 sec  
p59 fyn   53°C       80 sec 
 
 
1.5 Site directed mutagenesis 
The site-specific mutagenesis by overlap extension [28,30] uses two sets of mutagenic 
primers (R2/FM and RM/F2) and two successive PCR reactions in order to introduce a 
mutation into a desired location. The mutagenesis product is designed to contain restriction 
enzyme sites, which allow it to be cloned back into the vector. 
a. The mutagenic primers used were (MWG-Biotech):  
◦ Set of mutagenic primers for introducing mutations into the CD23-1 site within the 
CD23 promoter (pLuc+ACPmu) 
M256-R2 – 5’-TGT ATC TTA TCA TGT CTG GAT CTC GAA GCT TGC-3’ 
M257-FM – 5’-CAC GCA CAA CTT ATA CTGGCACTTCCCACACCC-3’ 
M258-RM – 5’-GTG TGG GAA GTG CCA GTA TAA GTT GTG CGT GTA AT-3’ 
M259-F2 –5’- TTT ACC AAC AGT ACC GGA ATG CCA AGC TCA G-3’. 
◦ Set of mutagenic primers for Tyr to Glu residues replacement in the 
pSosCD23a+Linker 
M320-FM- 5’-GGA GGA AGG TCA AGA ATC AGA GAT CGA GGA GCT T-3’ 
M321–R2 - 5’-CCC AAC CAG CTT TAA AAT GTC TGC AGA AAT GTA TTC-3’ 
M321–F2 - 5’-AAC GAG TTT ACG CAA TTG CAC AAT CAT GCT GAC-3’ 
M323–RM -5’-AAG CTC CTC GAT CTC TGA TTC TTG ACC TTC CTC C-3’ 
b. Reaction components (total of 100 µl): 
2 µl template pLuc+ACP (50ng/µl) 
3 µl downstream primer (10pmol/ml) 
3 µl upstream primer (10pmol/ml) 
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2 µl dNTP (10 mM each) 
1 µl Pfu DNA Polymerase (Stratagene) 
10 µl 10xPfu Buffer (Stratagene) 
79 µl H2O 
c. The conditions for all PCR reactions were:  
25 cycles - denaturation    1 min at 94°C,  
      annealing        1 min at 67°C (CD23-1 mutant); 68°C ( Tyr to Glu mutant) 
      elongation       1 min at 72°C  
1 cycle -    denaturation    1 min at 94°C  
      annealing        10 min at 72°C  
 
1.6 Nucleic acid cleaning and purification procedures 
PCR and RT-PCR products were either directly purified using QIAquick® PCR Purification 
Kit (Qiagen) or the bands were extracted from the agarose gel using QIA®quick Gel 
Extraction Kit (Qiagen) and MinEluteTM Gel Extraction Kit (Qiagen).  
DNA fragments resulted from enzymatic restriction were purified either by using QIAquick® 
Nucleotide Removal Kit (Qiagen) and MinEluteTM Nucleotide Removal Kit (Qiagen) or by 
gel extraction. 
 
1.7 Polishing of PCR products  
In order to increase the efficiency of blunt-ended cloning reactions, PCR generated fragments 
were polished using PCR Polishing Kit (Stratagene) according to manufacturer’s 
recommendations.  
 
1.8 Subcloning of PCR products 
Purified PCR and RT-PCR products have been cloned using the Zero BluntTM PCR Cloning 
Kit (Invitrogen). This kit is designed to clone blunt PCR fragments (or any blunt DNA 
fragment) with a low background of recombinants. The pCR®-Blunt vector allows direct 
selection of recombinants via desruption of a lethal E. coli gene, ccdB. Ligation of the insert 
into the linearized pCR-ZeroBlunt vector and transformation into the One ShotTM Top 10 
competent cells was done according to manufacturer’s instructions. The efficiency of ligation 
was assessed by restriction enzyme digestion with EcoRI or by a control PCR reaction 
following the protocol of the kit, except that bacterial colonies picked directly from the plate 
 31
were used instead of template DNA. Taq polymerase and Buffer Y (PeqLab) were used in 
this specific PCR reaction. 
 
1.9 DNA digestion with restriction enzymes 
The procedure was generally used to cut DNA fragments from one plasmid in order to insert 
it in the multiple cloning site of another plasmid or to analyse insertion or orientation of a 
DNA fragments into a vector.  
Reaction components: 
1 µg plasmid DNA 
2 µl 10x restriction enzyme Buffer 
5 U restriction enzyme 
H2O up to 20 µl 
The enzymatic reaction was incubated at 37°C for 1-4 hours. Enzymatic activity was stopped 
by heat inactivation, addition of 1xLoading dye or by freezing at –20°C. 
The following restriction enzymes (New England Biolabs) were used in different application: 
EcoRI, SalI, BamHI, HindIII, XhoI, XbaI, HpaII, AvrII, NaeI, etc. 
 
1.10 Klenow Fill-in reaction 
DNA Polymerase I, Large (Klenow) Fragment is a proteolytic product of E. coli DNA 
Polymerase I, which retains polymerization and 3’to 5’ exonuclease activity, but has lost 5’ 
to 3’ exonuclease activity. It was used for 3’-end labeling of DNA (described elsewhere), fill-
in of 5’ overhangs and removal of 3’ overhangs to form blunt ends. 
Reaction:  
0.1-4 µg DNA in 1x Klenow Reaction Buffer or 1x NEBuffer (NE Biolabs) 
1 µl dNTPs 0.5 mM each 
1µl (5U) Klenow (USB Corporation) 
The reaction was incubated for 60 minutes at 37°C. 
 
1.11 Dephosphorylation of DNA 
Alkaline phosphatase or Calf Intestinal Phosphatase (CIP) catalyses the removal of 5’ 
phosphate groups from DNA. Since 5’ phosphoryl termini are required by ligases, CIP 
treatment was used to prevent recircularization of vectors and thus to decrease the vector 
background in cloning strategies. 
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Reaction:  
DNA suspended in 1xNEBuffer 
CIP (NE Biolabs) 0.5 unit / 1 µg DNA 
The reaction was incubated for 60 minutes at 37°C. 
 
1.12 Ligation 
T4 DNA Ligase joins blunt and cohesive ends by catalyzing the formation of phosphodiester 
bonds between 5’ phosphate and 3’ hydroxyl termini. It was used for cloning restriction 
fragments into vectors. 
In all ligation reactions, an optimum insert: vector ratio of 5:1, expressed in pmol ends, was 
used. The following formula was used in order to assess the number of pmol ends in each 
case. 
pmol ends/ µg DNA=2x106 / bp x 660 
The typical ligation reaction (where x:y respect the above described ratio) was: 
x µl insert DNA 
y µl vector 
1 µl 10x T4 DNA Ligase Reaction Buffer (NE Biolabs) 
1 µl T4 DNA Ligase (NE Biolabs) 
H2O up to 10 µl 
The reaction was incubated at 16°C overnight. 
 
1.13 Transformation of bacteria 
Several Escherichia coli strains were used for transformation of different cloning vectors, in 
order to propagate, multiply or store different constructs. 
A standard transformation reaction is presented here: 
- competent cells were thawed on ice; 100 µl competent cells were aliquated in prechilled 
15 ml polypropylene tubes; 
- 1-50 ng of DNA per trasformation reaction was added; 
- the reaction was incubated on ice for 30 minutes; 
- the reaction was heat-pulsed in a 42°C water bath for 20-90 sec, depending on the strain 
used; the duration of the heat pulse is critical for transformation efficiency; 
- the reaction was incubated on ice for 2 minutes; 
- 900 µl SOC medium or LB medium per trasformation reaction were added; 
- the reaction was incubated at 37°C for 1 hour with shacking at 225-250 rpm; 
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- the cells were plated on LB agar plates containing the appropriate antibiotic; 
- the plates were incubated overnight at 37°C. 
 
1.14 Plasmid extraction 
Plasmid extraction was performed using NucleobondR AX (Macherey-Nagel), GenElute 
Plasmid Mini-prep Kit (Sigma) and WizardR Plus SV Minipreps DNA Purification Systems 
(Promega). 
 
1.15 Visualisation of DNA 
DNA fragments were visualised by running 1-1.5% agarose gels, depending on the size of 
the expected bands. 50 Base-Pair Ladder (Amersham Pharmacia) and peqGold 1 kb DNA-
Ladder (PeqLab) were used as markers. 
 
1.16 Sequencing  
Sequencing was mainly used to check the correct insertion of constructs or mutagenesis.  
a. The following sequencing primers (Gibco BRL) were generally used: 
M13F (universal primer)– 5’ –GTA AAA CGA CGG CCA G-3’ 
M13R (universal primer) – 5’-CAG GAA ACA GCT ATG AC-3’ 
M163 (pLuc+ reverse primer) –5’-CTT TAT GTT TTT GGC GTC TTC C-3’ 
M216 (pLuc+ forward primer) –5’-GCA TTC TAG TTG TGG TTT GTC C-3’ 
M78 (pSos 5’ primer)- 5’ –CCA AGACCA GGT ACC ATG-3’ 
M79 (pSos 3’ primer)- 5’ –CGC AGG GTT TTC CCA GT-3’ 
M215 (upstream of human Sos 5’ primer)- 5’ –CGT TCC CTT TCT TCC TTG-3’ 
M110 (pMyr 5’primer)- 5’ –ACT ACT AGC AGC TGT AAT AC-3’ 
M111 (pMyr 3’primer)- 5’ –CGT GAA TGT AAG CGT GAC AT-3’ 
b. Reaction components: 
4 µl ABI Prism®BigDyeTM Terminator (Applied Biosystems) 
0.5 µl forward or reverse primer (10nmol/µl) 
500 ng DNA 
H2O up to 20 µl 
c. PCR conditions: 
1 cycle- denaturation  3 min at 95°C 
25 cycles - denaturation 30 sec at 94°C,  
annealing  1 min at 50°C  
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elongation  3 min 60°C  
1 cycle - elongation 5 min at 72°C  
d. Purification of PCR products was performed using Auto-SeqTMG-50 columns 
(Amersham Pharmacia) according to manufacturer’s instructions. 
e. DNA precipitation: 20µl PCR product were precipitated with 80µl isopropanol 75%, 
vortexed and incubated for 15 min at room temperature, followed by centrifugation at 
top speed at room temperature for 20 minutes. After the removal of the supernatant 
the DNA pellet was washed with 250µl isopropanol 75%, mixed gently and 
centrifuged for another 5 minutes, top speed, at room temperature. The pellet was left 
to dry for 10-15 minutes at room temperature. 
f. Resuspention of DNA: the DNA pellet was resuspended in 18µl Template 
Suppression Reagent (Applied Biosystems)  
g. Denaturation of DNA: 3 minutes at 95°C in a heating block. 
 
 
2. Protein extraction   
 
2.1 Protein extraction from mammalian cells 
1x108 cells were resuspended in 200µl Roti®-Load1 (Roth) and heated at 80°C for 5 min. 
The lysate was then sonicated 4 x 10 sec, 50% power, followed by another 3 min at 80°C. 3 
µl of the lysate were used in Western Blot analyses. 
 
2.2 Protein extraction from yeasts 
5 ml overnight yeast culture with the O.D. >1 were pelleted at 4000xg, 10 min, 4°C and 
resuspended in 200 µl Cell Lysis Buffer for Protein Isolation with freshly added proteases. 
The cells were mixed with an equal volume of 0.5 mm glass beads (Roth) and vortexed for 5 
min at 4°C. After centrifuging for 5 min at 12000xg and 4°C the supernatant was transferred 
to a new 1.5 ml Eppendorf tube and kept on ice. The procedure was repeated with 100 µl of 
Cell Lysis Buffer for Protein Isolation and the supernatants were combined. 15-20 µl were 
used in Western Blot analyses. 
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3. Western Blot Analyses 
 
Western Blot analyses were performed in order to detect and quantify proteins by using 
polyclonal or monoclonal antibodies. 
a. Denaturing SDS-Polyacrylamide Gel Electrophoresis 
SDS-PAGE under denaturing conditions (0.1% SDS) separates protein based on molecular 
size as they move through a polyacrylamide gel matrix toward the anode. The 
polyacrylamide gel is cast as a separating gel topped by a stacking gel and secured in an 
electrophoresis apparatus.  
The final acrylamide concentration in the stacking gel is 4%, while the acrylamide 
concentration in the separating gel had to be adjusted according to the protein size. A 10% 
gel was used for Pax-5 (50 kDa) and a 6% gel for human SOS (170 kDa). The samples were 
solubilized in Roti®-Load1 (Roth) and loaded on the gel together with a prestained SDS-
PAGE Standard marker (Bio-Rad Laboratories). The electrophoresis was performed at 200V 
in an electrophoresis chamber (Hoefer) filled with Running Buffer. 
 
b. Immunoblotting  
After being separated by SDS-PAGE, the proteins were transferred using a semidry system 
(Panther Semidry Electroblotter- OWL) to a transfer nitrocellulose membrane (HybondTM 
ECLTM- Amersham Pharmacia) and stained by polyclonal or monoclonal antibodies. 
After disassembling the PAGE gel and discarding the stacking gel, the separating gel was 
equilibrated for 15 min in Cathode Buffer on an orbital shaker. The nitrocellulose membrane 
was prewet on distilled water and equilibrated for 15 minutes in Anode buffer II on an orbital 
shaker. 
The transfer stack was assembled as follows: 
Cathode electrode plate 
3 sheets of Whatman 3MM filter paper saturated with Cathode Buffer 
Gel 
Transfer membrane 
1 sheet of Whatman 3MM filter paper saturated with Anode Buffer II 
2 shees of Whatman 3MM filter paper saturated with Anode Buffer I 
Anode electrode plate 
The proteins were transferred for maximum 2 h at 0.8 mA/cm2. 
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c. Immunodetection 
Immunodetection was performed using the following protocol: 
y Blocking of the membrane- non-specific binding sites were blocked by incubating the 
membrane 1 hour at room temperature or overnight at 4°C in 5% dried milk, 0.1% Tween 
20 in PBS (Blocking Buffer) on an orbital shaker; 
y Rincing of the membrane- 3 times for 5 minutes with Wash Buffer on an orbital shaker; 
y Incubation with the primary antibody- the membrane was incubated with the primary 
antibody diluted in Blocking Buffer for 1 hour at room temperature on an orbital shaker. 
Anti Pax-5 and the anti SOS antibodies (BD Biosciences) were diluted 1:250; 
y Rincing of the membrane- 1x 15 minutes and 3x 5 minutes with Wash Buffer; 
y Incubation with the second antibody- the membrane was incubated with the secondary 
antibody –goat anti-Mouse IgG (BD Biosciences) diluted 1:2000 in Blocking Buffer for 1 
hour at room temperature on an orbital shaker; 
y Rincing of the membrane- 1x 15 minutes and 3x 5 minutes with Wash Buffer; 
y Visualisation of proteins –the presence of proteins was detected using ECL PlusTM 
Detection Kit (Amersham Pharmacia) and HyperfilmTM ECLTM chemiluminescence film 
(Amersham Pharmacia). 
 
 
4. Electrophoretic Mobility Shift Assays (EMSAs). 
 
This is a rapid and sensitive method for the detection of interaction between DNA-binding 
proteins and specific sequences of DNA. Proteins that bind specifically to an end-labeled 
DNA fragment retard the mobility of the fragment during electrophoresis, resulting in 
discrete bands corresponding to the protein-DNA complexes. 
 
4.1 Oligonucleotides 
The following annealed oligonucleotides (MWG-Biotech) were used as probes or as 
unlabeled competitors in direct binding or competition assays: 
y Pax-5 high affinity binding site from the sea urchin H2A-2.2 gene 
M118- 5' -CAG GGT TGT GAC GCA GCG GTG GGT GAC GAC TGT-3’ 
M119- 5’ -GCC ACA GTC GTC ACC CAC CGC TGC GTC ACA ACC-3’ 
y putative Pax-5 binding site CD23-1 (-87 to -47) 
M304 - 5' -GGG TGT GGG GAG CAC CAG GAG AGG CCA TGC GTG TAA TGT TA-3’ 
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M305 - 5’ -GGA  TAA CAT TAC ACG CAT GGC CTC TCC TGG TGC TCC-3’ 
y putative Pax-5 binding site CD23-2 (-112  to -71) 
M306 - 5’–CGG ACT TCA CCC GGG TGT GGG GAG CA-3’ 
M307 - 5’ –GGT GCT CCC CAC ACC CGG GTG AAG T-3’ 
y putative Pax-5 binding site CD23-3 (-238  to -209) 
M308 - 5’–GTG GTA TGA TTC AGT GTG CAG TAA CAG TGG TTC-3’  
M309 - 5’-GTG AAC CAC TGT TAC TGC ACA CTG AAT CAT A-3’ 
• CD23-1mu1 -mutated nucleotides are underlined 
M310 - 5’- GGG TGT GGG AAG TGC CAG TAT AAG TTG TG-3’ 
M311- 5’-ACG CAC AAC TTA TAC TGG CAC TTC CCA C-3’)  
y CD23-1mu2 -mutated nucleotides are underlined 
M265 - 5’- GTG TGG GGA GAA CCA GTA GAG GCC ATG CGT G-3’ 
      M266 - 5’- CAC GCA TGG CCT CTA CTG GTT CTC CCC A-3’ 
y A-1- CD23a promoter (-212 to –173) 
M37 - 5’- GGT TCA CAT CTT GAC GCT ACC ACT CAC CTC CTT CAG CCC-3’ 
M38 - 5’- AGG GCT GAA GGA GGT GAG TGG TAG CGT CAA GAT GTG-3’ 
• A-2- CD23a promoter (-178 to -140) 
M39 - 5’- AGC CCT GTG GGA ACT TGC TGC TTA ACA TCT CTA GT-3’ 
M40 - 5’- GAG AAC TAG AGA TGT TAA GCA GCA AGT TCC CAC AGG-3’ 
• A-3- CD23a promoter (-147 to -107) 
M41 - 5’- TAG TTC TCA CCC AAT TCT CTT ACC TGA GAA ATG GAG A-3’ 
M42 - 5’- GTT ATC TCC ATT TCT CAG GTA AGA GAA TTG GGT GAG AA-3’ 
• A-4- CD23a promoter (-115 to -75) 
M43 - 5’- GGA GAT AAT AAT AAC ACG GAC TTC ACC CGG GTG TGG G-3’ 
M44 - 5’- GCT CCC CAC ACC CGG GTG AAG TCC GTG TTA TTA TTA CT-3’ 
• A-5- CD23a promoter (-83 to -44) 
M45 - 5’- GTG GGG AGC ACC AGG AGA GGC CAT GCG TGT AAT GTT A-3’ 
M46 - 5’- GGA TAA CAT TAC ACG CAT GGC CTC TCC TGG TGC TCC-3’ 
• A-6- CD23a promoter (-51 to -9) 
M47 - 5’- TGT TAT CCG GGT GGC AAG CCC ATA TTT AGG TCT ATG AAA-3’ 
M48 - 5’- GTA TTT TCA TAG ACC TAA ATA TGG GCT TGC CAC CCG GAT A-3’ 
y A-7- CD23a promoter (-17 to +25) 
M49 - 5’- TGA AAA TAG AAG CTG TCA GTG GCT CTA CTT TCA GAA GA-3’ 
M50 - 5’- GCT TTC TTC TGA AAG TAG AGC CAC TGA CAG CTT CTA TTT-3’ 
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• A-8- CD23a promoter (+16 to +56) 
M51 - 5’- GAA GAA AGT GTC TCT CTT CCT GCT TAA ACC TCT GTC TC-3’ 
M52 - 5’- GTC AGA GAC AGA GGT TTA AGC AGG AAG AGA GAC ACT TT-3’ 
• A-9- CD23a promoter (+49 to +85) 
M53 - 5’- GTC TCT GAC GGT CCC TGC CAA TCG CTC TGG TCG AC-3’ 
M54 - 5’- GGG GTC GAC CAG AGC GAT TGG CAG GGA CCG TCA GA-3’ 
 
4.2 Radioactive labelling of annealed oligonucleotides 
Double stranded DNA fragments were radioactively labelled at the 3’-end by a typical 
Klenow Fill-in reaction in which dCTP was replaced by 32P-dCTP (Amersham Pharmacia 
and Hartmann Analytics). 
Reaction components (for a total of 25 µl): 
1 µl DNA (100ng/µl) 
1µl d(TGA)TP, 5 mM each 
5 µl α-32P-dCTP (10µCi/µl) 
1 µl (5 U) Klenow Fragments (USB Corporation) 
2.5µl 10x Klenow Fill-in Buffer (USB Corporation) 
13.5 µl H2O 
The reaction was incubated at 37°C for 30 min. Non-incorporated nucleotides were washed 
with the QIAquick® Nucleotide Removal Kit (Qiagen). The product was eluted in 80µl 
elution buffer and the incorporation of radioactive nucleotides was assessed using a 
scintillation counter. 
 
4.3 In vitro Transcription and Translation 
Human Pax-5 protein was obtained by in vitro transcription and translation using TNT®Quick 
Coupled Transcription/ Translation Systems (Promega) appropriate for vectors containing a 
promoter for T7 RNA polymerase. pCR-Pax-5 was used as template.  
 
4.4 Direct Binding and Competition Assays 
The method can be used to visualize protein-DNA interaction by direct binding assay, in 
which the protein binds a labeled oligonucleotide, or by competition assay, in which cold 
competitors are able to inhibit the formation of a complex between the protein and a labeled 
oligonucleotide. The specificity of the complexes formed is determined by supershifts, in 
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which antibodies added to the reaction bind to the protein–DNA complexes and retard the 
migration of the specific band. 
The basic reaction in direct binding assays was: 
2 µl 10x Pax-5 Binding Buffer 
2 µl in vitro translated Pax-5 protein 
1 µg poly[d(I-C)]  
40000 cpm 32P-labelled oligonucleotide (approximatively 0,5-1 ng) 
1 µg anti-Pax-5 antibody (BD Biosciences) – only in supeshift samples 
H2O up to 20 µl 
The reaction was incubated for 15 min at room temperature before adding: 
2 µl of 10x Loading Buffer. 
The basic reaction in competition assays was: 
2 µl 10x Pax-5 Binding Buffer  
2 µl in vitro translated Pax-5 protein 
1 µg poly[d(I-C)]  
2 µl of unlabeled oligonucleotides (1, 10 and 100ng/µl) 
H2O up to 20 µl  
The reaction was incubated for 10 min at room temperature before adding: 
40000 cpm 32P-labelled oligonucleotide (approximatively 0,5-1 ng) 
The reaction was incubated for 15 min at room temperature before adding:  
2 µl of 10x Loading Buffer. 
In all case the samples were run on nondenaturating 5% polyacrylamide gel at 15V/cm for 2 
hours. The gels were covered with plastic wrap, dried under vacuum and then exposed on 
BioMaxTM MS (Kodak scientific imagining film) at –80°C overnight. 
 
 
5. Ribonuclease Protection Assay 
 
The RPA is an extremely sensitive procedure for the detection and quantitation of mRNA in 
a complex sample mixture of total cellular RNA. 
In our case 5x106 U-937 cells where stimulated with IL-4 (50ng/ml), PMA (3ng/ml) or both 
for 48h. Total RNA was prepared in 1 ml TRIZOL reagent (Gibco) following manufacturer’s 
instructions. 
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5.1. Linearization of template DNA 
Plasmid DNA must be linearized with a restriction enzyme downstream of the insert to be 
transcribed, as circular plasmids will generate extremely long, heterogenous RNA transcripts. 
pBS-CD23a, the template plasmid for CD23 transcripts was linearized with EcoRI restriction 
enzyme; pBS-β-actin, the template plasmid for β-actin, which was used as an internal 
control, was linearized with XbaI restriction enzyme. The linearized plasmids were observed 
on a 1 % agarose gel and the bands were extracted with QIAquick® Gel Extraction Kit 
(Qiagen). 
 
5.2. In vitro Transcription   
In vitro transcription was performed using [α-32P] UTP (Amersham Pharmacia) as 
radiolabeled nucleotide and MAXIscript TM T7/T3 (Ambion) In vitro Transcription Kit 
following manufacturer’s instructions. Transcription products were purified using 
MicroSpinTMS-200 HR Columns (Amersham Pharmacia) and run on a denaturing 5 % 
polyacrylamide/urea gel at 200V for 1 hour. The disassembled gel was kept on one plate, 
covered with plastic wrap and exposed for 4 min on Sterling film (Diagnostic Imaging). 
Using the film as a template, the full length RNA band was excised from the gel. The RNA 
transcripts were eluted overnight, at 37°C in elution buffer from the HybSpeed TM RPA Kit 
(Ambion). The incorporation of radioactive nucleotides was assessed using a scintillation 
counter. The probes gave rise to a 299 bp band for CD23a, a 184 bp band for CD23b and a 
double band around 130 bp for β-actin.  
 
5.3. Hybridization reaction  
Hybridization reaction was carried on using HybSpeed TM RPA Kit (Ambion) according to 
manufacturer’s instructions except hybridization was extended overnight. Results were 
assessed by autoradiography on BioMaxTM MS (Kodak Scientific Imaging Film) at –80°C 
for 24-72 hours. 
 
 
6. Transfection and reporter gene assay 
 
Transient transfection assays are used for analysing mammalian gene expression in vivo. 
Fusion genes constructs consisting of promoter or enhancer sequences under study attached 
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to a gene directing the synthesis of a reporter molecule are used to assess gene expression 
within 48 hours after introduction of the DNA. Luciferase assay use the luc gene of the 
firefly as a reporter gene and yields light signals that can be detected using an automated 
injection luminometer. 
 
6.1 Transfection   
3x105 293 cells were transfected with 100 ng of the pLuc+ vectors and 500 ng of the 
pcDNA3-Pax-5 and pXM-STAT6 vectors. DNA concentration was brought to a total of 2µg 
DNA / transfection using salmon sperm DNA (Amersham Pharmacia). Transfection was 
performed in 1 ml trasfection volume using GenePORTERTM Transfection Reagent (PeqLab) 
according to manufacturer’s instructions, except that growth medium was completely 
renewed 24 hours post transfection. Four hours after transfection cells were stimulated with 
IL-4 to a final concentration of 50ng/ml (rIL-4 provided by Prof. Sebald, Biozentrum, 
University of Würzburg) and PMA to a final concentration of 3ng/ml (Sigma). 
 
6.2 Cell Lyses and Luciferase Assay 
Cells were removed by pipetting up and down, collected in 15 ml tubes and washed 2 times 
with cold PBS followed by centrifugation at 1200xg, 10 min, 4°C. Pellets were left to dry at 
room temperature and then resuspended in 1x Reporter Lysis Buffer (Promega). The 
luciferase activity was assessed following manufacturer instructions- Luciferase Assay 
System (Promega) using a luminometer (Berthold). The results were normalized for equal 
concentration of total protein. 
 
 
7. Transfection/ Infection Assays  
 
Transfection of U-937 cells with the recombinant vector pEGZ-Pax-5 has been performed by 
Dr. I. Berberich (Institute for Virology and Immunobiology, Würzburg). Recombinant 
retroviral particles were generated using the pHIT packaging system as described by Soneoka 
et al [47].  
Briefly, 293T cells were transiently cotransfected using the standard calcium phosphate 
method with 5 µg of each of the packaging vectors pHIT456 (which codes for the 
amphotropic env protein) and 5-7 µg of the retroviral construct pEGZ/MCS and EGZ/Pax-5.  
Sixteen hours later the transfection solution was replaced by DMEM. Viral supernatants were 
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harvested 48h later and filtered (0.45µm). Polybrene (Sigma) was added to a final 
concentration of 10µg/ml. U-937 cells were mixed with the retroviral supernatant and 
centrifuged for 3 hours at 1000 x g. Thereafter cells were replated in RPMI. Transduced cells 
were selected with Zeocin (250 µg/ ml).  
The cell line selected for experiments stained positive for EGZ in 97% of the cells, as 
revealed by FACS analysis. 
 
 
8. Nucleic acid extraction 
 
8.1 DNA extraction 
DNA was extracted from 1x 108 cells using QIAampR DNA Blood Kit (Qiagen) following 
manufacturer’s instructions. 
 
8.2 RNA extraction 
y Homogenisation- 1x107 mammalian cells were pelleted by centrifugation and lysed in 1.5 
ml Trizol Reagent by repetitive pipetting.  
y Phase separation- The homogenized samples were incubated for 5 minutes at room 
temperature to permit the complete dissociation of nucleoprotein complexes. 0.3 ml 
chloroform was added and tubes were shacked vigorously by hand for 15 seconds and 
incubated at room temperature for 2 to 3 minutes. Then samples were centrifuged at 
12,000 x g for 15 minutes at 4°C. Following centrifugation, the mixtures separated into a 
lower red, phenol-chloroform phase, an interphase and a colourless upper aqueous phase. 
RNA remains exclusively in the aqueous phase. 
y RNA precipitation- The aqueous phase was transferred to a new tube and the RNA 
precipitated by mixing with 0.75ml isopropanol. Then samples were incubated at room 
temperature for 10 minutes and centrifuged at 12000x g for 10 minutes at 4°C. The RNA 
precipitate was visible as a gel-like pellet. 
y RNA wash- After removal of the supernatant the pellet was washed once with 1.5ml of 
75% ethanol. The samples were mixed by vortexing and centrifuged at 7,500x g for 5 
minutes at 4°C. 
y Redissolving the RNA- After discarding the ethanol the RNA pellet was air-dried for 5-
10 minutes and dissolved in RNase-free water by passing the solution a few times 
through a pipette tip and incubating for 10 minutes at 55 °C. 
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9. Spectrophotometric measurements 
 
9.1 Nucleic acids 
To assess the concentration of nucleic acids in a sample absorbtion is measured at 260 
wavelenght. Absorbance at 280 wavelengths is measured to assess the purity of the sample. 
The A260/A280 ratio is used to estimate the purity of the sample and should be between 1.6 
and 2. To determine the nucleic acid concentration (in µg/ml) the A260 reading has to be 
multiplied with a factor of 50 for double stranded DNA, 33 for single stranded DNA and 40 
for RNA.  
 
9.2 Proteins 
For measuring the protein concentration 10 µl protein solution were diluted in 190 µl H2O 
and 800 µl 1x RotiR- Nanoquant (Roth). The absorbtion of the sample is measured at 590 and 
450 wavelenghts. The A590/A450 ratio was introduced into a linear regression program in 
order to determine the total protein concentration in the sample. 
 
 
10. Two Hybrid Systems  
 
10.1 CytotrapTM Two Hybrid System (Stratagene) 
This is a novel method for detecting in vivo protein-protein interaction, which is based on 
generating fusion proteins whose interaction in the yeast cytoplasm induces cell growth by 
activating the Ras signaling pathway. 
The system provides: 
- the host strain cdc25H 
- the vectors: the bait vector (pSos), the target vector (pMyr) and control vectors (pSos 
MAFB, pSos Coll, pMyr MAFB, pMyr Lamin C)  
The human spleen cDNA library cloned in the pMyr vector was purchesed from Stratagene 
and amplified following manufacturer’s instructions. 
All protocols and procedures for the CytoTrap Two Hybrid System were carried on 
following manufacturer instruction, with a few modifications, as noted: 
 
y Preparation and Trasformation of Yeast Competent Cells- was performed using the 
following protocol [91]: 
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- 5 ml of liquid YPAD were inoculated with one colony of yeast and shacked at 250 
rpm, overnight, at 25°C. 
- The overnight culture was used to inoculate 50 ml of YPAD and incubated up to a 
cell density of 0.7 OD. 
- The culture was harvested in a sterile 50 ml tube at 3000xg for 5 minutes, at room 
temperature. 
- The cells were resuspended very gently in 25 ml sterile water and centrifuged again. 
- The pellet was resuspended in 1 ml 100mM lithium acetate (LiAc) and transferred to 
a 1.5 ml centrifuge tube. 
- The cells were centrifuged for 5 sec at top speed in a table-top centrifuge and the 
LiAc was removed with a pipette. 
- The cell were resuspended in a final volume of 500 µl 100mM LiAc 
- 50 µl of cell suspension were pipetted in labeled microfuge tubes and centrifuged for 
5 sec at top speed; LiAc was removed with a pipette. 
- A “transformation mix” was assembled as follows, strictly respecting this order: 
240 µl PEG (50%w/v) 
36 µl 1.0 M LiAc 
25 µl single-stranded carrier DNA (2mg/ml) previously boiled for 5 min        
and placed directly on ice 
50 µl H2O and plasmid DNA (1-3 µg) 
- Each tube was vortexed vigorously until the cell pellet was completely mixed and 
incubated at room temperature for 30 minutes. 
- Tubes were heat-shocked for 20 minutes in a water bath at 42°C. 
- Tubes were centrifuged at 6000-8000 rpm for 15 sec and the transformation mix with 
a pipette. 
- The pellets were resuspended in 250µl sterile water by gently pipetting up and down 
and plated onto selective plates. 
 
y Isolation of pMyr cDNA plasmids from Yeasts –was performed using a RPM Yeast 
Plasmid Isolation Kit (Bio101). 
 
The chart flow of a screening episode is schematically presented in Figures 8-11. 
Briefly, the screening steps were as follows: 
- pSosCD23a/b and pMyr spleen library  were co-transformed in the cdc25H yeast strain; 
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- transformation products were plated on Glucose(-Ura, -Leu) 150 mm plates and incubated 
at 25°C for 58-60 hours;  
- the yeast colonies were replica plated on Galactose(-Ura, -Leu) plates and incubated for 6-
10 days at 37°C; 
- every colony which appeared after replica plating was tested on Glucose(-Ura, -Leu) and 
Galactose(-Ura, -Leu) at 37°C in order to distinguish between temperature revertants and 
real interactions;  
- the phenotype was checked: colonies that grew on glucose at 37°C were considered 
“temperature revertants” (the presence of glucose in the medium inhibits the GAL1 
promoter which controls the expression of the fusion protein in the pMyr construct, in such a 
way that library proteins are not expressed when the yeast host is maintained on glucose). 
Colonies that grew at 37°C on galactose but not on glucose reflected a real interaction (Fig. 
8); 
- plasmids were extracted from yeasts, transformed in bacteria and plated on LB agar plates 
containing chloramphenicol, the selection for the pMyr vector (Fig.9); 
- plasmids extracted from bacteria were analysed by enzymatic restriction with XbaI (two 
XbaI  sites flank the MCS of the pMyr vector);  
- every pMyr-library profile obtained by XbaI digestion in yeasts was co-transformed 
together with pSosCD23a/b (Fig.10); 
-  the interaction was checked on Glucose(-Leu,-Ura) and Galactose(-Leu,-Ura) selective  
plates at 37°C; 
- the phenotype was checked (Fig.10). By-standing library constructs that co-transform 
together with those pMyr-library plasmids which cause a real interaction were excluded at 
this stage; 
- pMyr-library clones were co-transformed in yeasts together with  pSos or pSosColl 
(Fig.11); 
- the transformants were patched on Glucose(-Leu,-Ura) and Galactose(-Leu,-Ura) selective  
plates at 37°C; 
- the phenotype was checked: transformants that grew on Galactose(-Leu,-Ura) at 37°C were 
considered “false positive” (the interaction involves human SOS protein, not the bait). 
Transformants that didn’t grow on Galactose(-Leu,-Ura) at 37°C were considered “true 
positive” (they could be subjected to further analyses). 
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10.2 MATCHMACKER GAL 4 Two-hybrid System 3 (Clontech) 
This system is an advanced GAL4-based two-hybrid system that provides a transcriptional 
assay for detecting protein interactions in vivo in yeasts. 
The system provides: 
- the host strains: AH109 and Y187 
- the vectors: the bait vector (pGBKT7), the target vector (pGADT7) and control 
vectors (pGBKT7-T, pGBKT7-53, pGBKT7-Lam, pCL1)  
All protocols and procedures for the MATCHMACKER GAL 4 Two-hybrid System 3 were 
carried on following manufacturer instruction. 
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Fig.8  The chart flow of the CytoTrap screening: eliminating the temperature revertants 
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11. Materials 
 
11.1 Buffers 
 
10x Pax-5 Binding Buffer   100mM HEPES pH 7,9 
1M KCl 
40% Ficoll 
10mM EDTA 
10mM DTT 
Cell Lysis Buffer for Protein Isolation 140 mM NaCl 
2.7 mM KCl 
10mM Na2HPO4 
1.8 mM KH2PO4 
1% Triton X 
+ Protease inhibitors 1mM PMSF 
10µg/ml aprotinin 
1µM pepstatin A 
100µM leupeptin 
1µg/ml chymostatin 
Running Buffer for SDS-PAGE  3.03 g Tris 
14.4 g glycin 
1 g SDS 
H2O up to 1 liter 
Anode Buffer I    0.3 M Tris 
10% methanol 
Anode Buffer II    25 mM Tris 
10 % methanol 
Cathode Buffer    25mM Tris 
40mM 6- amino n- caproic acid 
10 % methanol 
Wash Buffer     100 ml PBS (10x) 
      1 ml Tween 20 (0,1%) 
      900 ml H2O 
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Blocking Buffer    1x PBS 
 0.1% Tween 20  
5% dry milk 
10 x Loading Dye (EMSA)   20% Ficoll 
0,1 M Na2EDTA pH 8,0 
1 % SDS 
0.25 % bromphenolblue 
0.25 % xylene cyanol 
6 x Loading Dye (Agarose gel)  0.25 % bromphenol blue 
      0.25 % xylen cyanol 
      30 % glycerol in water 
TAE electrophoresis buffer (50x)  242 g Tris base  
      57.1 ml glacial acetic acid 
      37.2 g Na2EDTA⋅2H2O 
      H2O up to 1 liter 
TBE electrophoresis buffer (10x)  108 g Tris base 
      55 g boric acid  
      40 ml 0.5 M EDTA, pH 8.0 
      H2O up to 1 liter 
 
11.2 Gels 
 
Laemmli Gel (PAGE) 
     Separating gels          Stacking gels 
         6%    10%       4% 
Acrylamyde 30%    1.99 ml  3.32 ml  0.67 ml 
Tris 1M, pH 8,8    3.75 ml  3.75 ml 
Tris 1M, pH 6,8        0.625 ml 
10% SDS      0.1 ml  0.1 ml   0.05 ml 
H2O       4.12 ml  2.78 ml  3.625 ml 
10% ammonium persulphate    50 µl   50 µl   25 µl 
TEMED      3.3 µl  3.3 µl   2.5 µl 
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Nondenaturing 5 % polyacrylamide gel (for EMSA) 
Acrylamide 30 %   6.67 ml 
10 x TBE    2 ml 
H2O     31.33 ml 
TEMED    40 µl 
10% ammonium persulphate  400 µl 
 
Denaturing 5 % polyacrylamide/urea gel (for RPA) 
Acrylamide 40 %   6.3 ml 
10 x TBE     5 ml 
Urea      24 g  
H2O     up to 50 ml 
10 % ammonium persulphate  300 µl 
TEMED    34 µl 
 
Agarose gel 
Agarose UltraPure (Gibco BRL) 1-1.5 % 
1 x TAE 
Ethidium bromide  ( 0.5 µg /ml) 
 
11.3 Media for bacteria and yeasts 
LB Broth Base(Gibco BRL) 
LB Agar (Gibco BRL) 
Ampicillin (USB Corporation) 
Chloramphenicol (Roche) 
Kanamycin (USB Corporation) 
DOB-Dropout Base (BIO 101) 
DOBA-Dropout Agar base (BIO 101) 
DOBA, 2% Gal, 1% Raf (BIO 101) 
YPD Broth (BIO 101) 
Agar-Agar (Roth) 
CSM-Leu-Ura (BIO 101) 
CSM-His-Leu-Trp (BIO 101) 
CSM-His-Leu-Trp-Ura (BIO 101) 
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Adenine (Sigma) 
L-Histidine (Sigma) 
L-Leucine (Sigma) 
L-Tryptophan (Sigma) 
Uracil (Sigma) 
X-α-Gal (Clontech) 
 
11.4 E.coli competent cell strains 
DH5α 
Epicurian Coli® BL21-Codon PlusTM (Stratagene) 
One ShotTM Top 10 (Invitrogen) 
 
11.5 Cell lines 
• The 293 cell line is a permanent line of primary human embryonal kidney transformed 
by sheared human adenovirus type 5 (Ad 5) DNA. The cells were maintained in DMEM 
(Gibco) supplemented with L-Glutamine (2mM), antibiotics (Penicillin 100U / 
Streptomycin 100µg/ml) and 10% FCS. 
• The U-937 cell line is a monoblastoid cell line. The cells were maintained in RPMI 1640 
(Gibco) supplemented with L-Glutamine (2mM), antibiotics (Penicillin 100U / 
Streptomycin 100µg/ml) and 10% FCS. 
• The WIL2 cell line is an Epstein-Barr virus infected B cell line. The cells were 
maintained in RPMI 1640 (Gibco) supplemented with L-Glutamine (2mM), antibiotics 
(Penicillin 100U / Streptomycin 100µg/ml) and 10% FCS. 
 
11.6 Software and websites 
y DNAsis 
y JellyFish 
y pDRAW 
y Kodak Imager 
y Miscrosoft Office 
y WebPrimer- http://genome-www2.stanford.edu/cgi-bin/SGD/web-primer 
The Web Primer provides tools for the purpose to design primers. Current choices are 
limited to sequencing and PCR.  
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y NCBI Entrez Nucleotide- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide 
The Entrez Nucleotides database is a collection of sequences from several sources, including 
GenBank, RefSeq, and PDB.  
y NCBI BLAST- http://www.ncbi.nlm.nih.gov/BLAST/ 
BLAST® (Basic Local Alignment Search Tool) is a set of similarity search programs 
designed to explore all of the available sequence databases regardless of whether the query is 
protein or DNA. The scores assigned in a BLAST search have a well-defined statistical 
interpretation, making real matches easier to distinguish from random background hits. 
 
 
11.7 Lab devices 
GeneAmp PCR System 2400 (Perkin Elmer) 
ABI PRISMTM 310 Genetic Analyser (Applied Biosystems)  
Digital camera 
Ultrospec 1000 spectrophotometer (Amersham Pharmacia) 
MicroLumat LB 96P luminometer (EG&G Berthold) 
Optimax Developer (Protec) 
Scintillation counter (Beckman LS 1801) 
Vacuum dryer 
Sonicator 
Incubators 
Shackers 
Autoclaves 
Centrifuges 
Heating blocks 
Water bath 
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RESULTS 
 
 
 
 
 
1. The CD23a promoter- role of Pax-5 in the B-cell specific 
expression of CD23a isoform 
 
 
 
1.1 The CD23a core promoter contains three putatitive binding sites for Pax-5 
 
The consensus motif for Pax-5 has been characterised by Czerny et al. in an extended 
comparison between all known natural ligands of Pax-5, including the recognition sequences 
which originates from the sea urchin H2A-2.2 gene and the human CD19 gene [12]. 
Our approach to test the hypothesis of Pax-5 regulating the expression of CD23a isoform 
was to identify putative binding sites for Pax-5 in the CD23a promoter. We performed 
multiple sequence alignments between the CD23a core promoter (Fig. 12A) and the Pax-5 
consensus sequence. Three putative Pax-5 binding sites were identified in positions -61 to -
79, -78 to -96 and -215 to -233 of the CD23a promoter (Fig. 12) and named CD23-1, CD23-
2 and CD23-3 respectively.  
All naturally occurring Pax-5 binding sites identified so far deviate from the consensus 
sequence and Pax-5 is able to interact with a panel of seemingly degenerate recognition 
sequences. This makes the prediction of Pax-5 binding sites quite difficult, when only 
relating to the sequence of the promoter. When chosing the putative Pax-5 binding sites, we 
considered only the sites with at least 50% identity to the consensus sequence.  Fig. 12B 
shows the sequence alignment of these three putative binding sites with the consensus motif 
and other previously identified Pax-5 binding sites from the sea urchin H2A-2.2 and CD19 
genes. The CD23-3 putative binding site displayed the highest homology with the consensus 
motif (89%). A gap had to be introduced in the putative binding site CD23-1 in order to 
reconstitute the symmetry of the recognition sequence. 
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B                                        5’     3’ 
   A                                     GA     GG 
CONSENSUS                   G .  . C A .  TG  .  . GC GTGAC CA  
 
  
H2A-2.1           TTGTGACGCAGCGGTGGGTGAC GACTGT  
 
CD19-1            CAGACACCCATGGTTGAGTGCCCTCCAG 
 
CD19-2           AGAATGGGGCCTGAGGCGTGACCAC CGC  
 
CD23-1           GTGGGGAGCACC_AGGAGAGGCCATGCG         6 5%  
 
CD23-2            ACGGACTTCACC CGGGTGTGGGGAGCAC        57%  
 
CD23-3            GTATGATTCAGTGTGCAGTAACAGTGGT         89%               
 
 
 
 
 
  1    2    3   4    5    6    7   8    9  10   11 12  13  14  15 16  17  18  19  20  21  22  23  24 25  26 27 28       
Fig.12 CD23a core promoter and consensus recognition sequences for Pax-5. (A) CD23 core 
promoter (-243 to +82): The three putative Pax-5 binding sites are shown with the homologous 
nucleotides shaded. The boxes represent the synthetic oligonucleotides containing the three putative 
binding sites: CD23-1, CD23-2 and CD23-3. The STAT6 binding site (IL-4 responsive element) is 
underlined; the localization of NF-kB binding sites is indicated by analogy with the murine CD23 
promoter. The arrows (position 1 and 16) show the beginning of exon Ia (5' UTR). (B) Pax-5 
recognit ion sequences: The three putative Pax-5 binding sites - CD23-1, CD23-2, CD23-3 are shown 
in comparison with Pax-5 binding sites from the sea urchin H2A-2.2 and the human CD19 promoters. 
The orientation of the sequences corresponds to the natural orientation of the Pax-5 binding sites. 
Consensus sequences are shaded and the deduced consensus sequence is shown above. 
  
 
         A 
     “X Box”   CD23-3     TRE 
ATAGTGGTATGATTCAGTGTGCAGTAACAGTGGTTCACATCTTGACG 
          EBNA-1(CBF1)           “Y Box” 
CTACCACTCACCTCCTTCAGCCCTGTGGGAACTTGCTGCTTAACATCTC 
   C/EBP        IL-4 RE     
TAGTTCTCACCCAATTCTCTTACCTGAGAAATGGAGATAATAATAACA 
     NF-kB CD23-2         NF-kB             CD23-1       
CGGACTTCACCCGGGTGTGGGGAGCACCAGGAGAGGCCATGCGTGTAA 
TGTTATCCGGGTGGCAAGCCCATATTTAGGTCTATGAAAATAGAAGCT 
GTCAGTGGCTCTACTTTCAGAAGAAAGTGTCTCTCTTCCTGCTTAAACC 
TCTGTCTCTGACGGTCCCTGCCAATCGCTCTGGTCGA 
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1.2 Pax-5 protein interacts with the CD23-1 binding site from the CD23a core promoter 
in vitro 
 
1.2.1 CD23-1 binding site competes a high affinity Pax-5 binding site 
We tested the three putative binding sites for their ability to bind Pax-5 protein. In a first 
stage synthetic oligonucleotides were used in EMSA competition experiments as cold 
competitors. The oligonucleotides were designed to cover regions in the CD23a promoter 
ranging from -84 to -47 for CD23-1, -112 to -71 for CD23-2, and -238 to -209 for CD23-3 
putative sites. Their localization within the CD23a core promoter is represented in Fig. 10A 
as rectangles. As a labelled probe, an oligonucleotide representing the high affinity Pax-5 
binding site from the sea urchin H2A-2.2 gene was used (Fig. 12B). Pax-5 was synthesized 
by in vitro transcription and translation. The plasmid construct used for Pax-5 translation 
generated an additional unspecific band (Fig.13A, lane 1). Under these conditions, supershift 
experiments using a monoclonal Pax-5 antibody verified the correct DNA-protein complex 
(Fig. 13A, lanes 2-3).  
Complex formation was inhibited by a 10-fold excess of the oligonucleotide CD23-1, but not 
by an excess of oligonucleotides CD23-2 and CD23-3. For comparison, we also competed 
the high affinity Pax-5 binding site H2A-2.2 with itself (Fig. 13A, lanes 4-6). CD23-1 
showed approximatively a 10 times lower affinity than the H2A-2.2 binding site. Both 
CD23-2 and CD23-3 oligonucleotides failed to compete the high affinity binding site. 
 
 1.2.2 CD23-1 binding site interacts with Pax-5 protein directly 
To confirm the results obtained in competition assays, the same oligonucleotides 
representing the putative CD23-1, CD23-2 and CD23-3 sites were appropriately labeled and 
checked for direct binding (Fig. 13B). The specificity of the complexes formed was 
confirmed by supershifts using a monoclonal antibody against Pax-5. CD23-1 was the only 
site where we observed a specific complex formation with Pax-5 (Fig. 13B, lanes 4-5). Both 
competition experiments and direct binding approaches indicated CD23-1 putative site as a 
Pax-5 binding site. 
 
1.3 Mutations of the CD23-1 binding site prevent Pax-5 binding 
 
To further analyse the CD23-1 site we constructed oligonucleotides in which the Pax-5 
binding site was mutated and tested again their ability to interact with Pax-5 in EMSAs.  
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Fig.13 CD23-1 binding site interacts with Pax-5. (A) An oligonucleotide containing the optimal 
Pax-5 binding site from the sea urchin H2A-2.2 gene was radioactively labeled and incubated with 
Pax-5 protein obtained by in vi tro transcription and translation. Unlabeled ol igos representing the 
optimal Pax-5 binding site H2A-2.2 (lanes 4-6) or containing the three putative Pax-5 binding sites 
from the CD23a promoter (lanes 7-15) were used as competitors (ratios of 1:1,1:10 and 1:100 labeled 
H2A-2.2 to unlabeled competi tor). Lane 1 shows the empty vector (pCR) used for in vi tro transcription 
and translation of the Pax-5 protein incubated with the labeled oligonucleotide,  which forms an 
unspecific complex ( ). Lane 2: specific Pax-5 complex. Lane 3: Pax-5 supershift with anti Pax-5 
antibody. (B) Oligonucleotides containing the optimal Pax-5 binding site from the sea urchin H2A-2.2 
gene (lanes 2-3) and the three putative Pax-5 binding sites from  the CD23a promoter (lanes 4-9) were 
radioactively labeled and incubated with Pax-5 protein obtained by in vitro transcription and 
translation. Pax-5 antibody was added to check the specificity of the bands (lanes 3, 5, 7, 9). Lane 1 
shows the empty vector (pCR) used for in vi tro transcription and translation of the Pax-5 protein 
incubated with the labeled high affinity site; ( )-unspecific complex. 
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CD23-1            GTGGGGAGCACCAGGAGAGGCCATGCGTGTAATGTTA
CD23-1 mu1    GTGGGAAGTGCCAGTATAAGTTGTGCGTGTAATGTTA
CD23-1 mu2    GTGGGGAGAACCAGTAGAGGCCATGCGTGTAATGTTA   
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Fig. 14 Mutations in the CD23-1 binding site prevent Pax-5 binding. (A) CD23-1mu1 and 
CD23-1 mu2 oligonucleotides contain mutated variants of the CD23-1 putative Pax-5 binding site. 
Mutated nucleotides are underlined. (B) An oligonuclotide containing the high affinity Pax-5 binding 
site from the sea urchin H2A-2.2 gene was radioactively labeled and incubated with Pax-5 protein 
obtained by in vitro transcription and translation. Unlabeled oligos containing mutated variants of the 
CD23-1 putative binding sites (lanes 4-9) were used as competitors (ratios of 1:1,1:10 and 1:100 
labeled H2A-2.2 to unlabeled competitor). Lane 1 shows the empty vector (pCR) used for in vitro 
transcription and translation of the Pax-5 protein incubated with the labeled oligonucleotide, which 
forms an unspecific complex ( ). Lane 2: specific Pax-5 complex. Lane 3: Pax-5 supershift. (C) 
Oligonucleotides containing the putative CD23-1 binding site (lanes 2-3) and mutated sites CD23-
1mu1 and CD23-1mu2 (lanes 4-7) were radioactively labeled and incubated with Pax-5 protein 
obtained by in vitro transcription and translation. Pax-5 antibody was added to check the specificity of 
the bands (lanes 3, 5, 7). Lane 1 shows the empty vector (pCR) used for in vitro transcription and 
translation of the Pax-5 protein incubated with the labeled CD23-1 site; ( )-unspecific complex. 
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Fig.15 CD23-1 is the only site in the CD23a core promoter that directly binds Pax-5. (A) 
CD23 core promoter (-243 to +82): The boxes represent the overlapped synthetic oligonucleotides 
spanning the promoter: A-1 to A-9. The STAT6 binding site (IL-4 responsive element) is 
underlined; the arrows (position 1 and 16) show the beginning of exon Ia (5' UTR). (B) An 
oligonucleotide containing the optimal Pax-5 binding site from the sea urchin H2A-2.2 gene was 
radioactively labeled and incubated with Pax-5 protein obtained by in vitro transcription and 
translation. Unlabeled synthetic oligonucleotides A-1 to A-9 (lanes 4-30) were used as competitors 
(ratios of 1:1,1:10 and 1:100 labeled H2A-2.2 to unlabeled competitor). Lane 1 shows the empty 
vector (pCR) used for in vitro transcription and translation of the Pax-5 protein incubated with the 
labeled oligonucleotide, which forms an unspecific complex. Lane 2: specific Pax-5 complex. Lane 
3: Pax-5 supershift with anti Pax-5 antibody. ( )-unspecific complex. 
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CD23-3
CD23-1
CD23-2
Since Pax-5 is able to interact with a panel of seemingly degenerate recognition sequences it 
is quite difficult to predict which nucleotides are essential in the protein-DNA interaction 
[12]. For this reason we created two different mutated variants of the CD23-1 putative site 
(Fig. 14A). In CD23-1mu1 all 9 nucleotides considered to be responsible for creating the 
Pax-5 binding site were mutated. CD23-1mu2 contains only two substitutions (C to A in 
position 4 and G to T in position 11 of the consensus motif), as these nucleotides seem to act 
like key points for Pax-5-DNA interaction [3,12].  
The ability of the two mutant oligonucleotides to bind to Pax-5 protein was subsequently 
tested in EMSAs. As seen in Fig. 14B, both oligonucleotides CD23-1mu1 and CD23-1mu2 
containing the mutated CD23-1 binding site were unable to compete, at any concentration, 
the sea urchin high affinity H2A-2.2 Pax-5 binding site. Direct binding assays showed that 
the oligonucleotides containing the mutated sites failed to bind Pax-5 protein anymore (Fig. 
14C). These results give additional evidence that CD23-1 is a Pax-5 binding site since 
mutations introduced in this site completely abrogate the binding of the protein. 
 
1.4 CD23-1 is the only site which directly binds Pax-5 protein 
 
We considered the possibility that other putative sites, which displayed less than 50% 
homology with the consensus sequence, might bind Pax-5 anyway. Nine pairs of overlapping 
oligonucleotides, named A1-A9, covering the whole lentgh of the CD23a core promoter (Fig. 
15A) were synthesized and used as competitors for the sea urchin H2A-2.2 binding site in 
EMSAs. As seen in Fig. 15B, the oligonucleotide A5, which covers the putative binding site 
CD23-1, was the only one to compete the high affinity binding site. This approach confirmed 
previous results, pointing for CD23-1 as the only site within the CD23a core promoter that 
can directly bind Pax-5. 
 
1.5 Pax-5 mediates activation of the CD23a promoter in vitro 
 
To examine the effect of Pax-5 on the activation of the CD23a promoter a luciferase reporter 
construct containing the CD23a core promoter (from position -203 to position +83) cloned in 
the pLuc+ vector was made and named pLuc+ACP (CD23a core promoter). Another 
construct, pcDNA3-Pax-5 was used for ectopic expression of Pax-5. 293 cells were 
transfected with the luciferase construct pLuc+ACP alone or together with pcDNA3-Pax-5. 
Luciferase activity was determined after 40 hours under non-stimulating conditions or after 
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Fig.16 Pax-5 mediates the activation of the CD23a promoter. (A) Schematic representation of the
reporter constructs  used. (B) 293 cells were transfected with the vector containing the Cd23a core promoter
(pLuc+ACP WT, positions -203 to +83) and the vector containing the CD23a core promoter in which the
nucleotides of the putative Pax-5 binding site CD23-1 were mutated (pLuc+ACPmu). Where indicated 
cells were co-transfected with pcDNA3-Pax-5. Luciferase activity was assayed after 40 hours under nonstimulatory
conditions or after stimulation with IL-4 (50ng/ml) and PMA(3ng/ml). The average luciferase value of 
3 independent experiments is shown. Error bars indicate st andard deviation of the mean. (C) 293 cells were 
transfected with the vector containing the CD23a promoter (pLuc+AP, positions -1216 to +211) together with 
pcDNA3-Pax-5 and pXM-STAT6 as indicated. Luciferase activity was assayed after 40h.The average luciferase 
value of three independent experiments is shown. Error bars indicate standard deviation of the mean.
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 stimulation with PMA and IL-4. As shown in Fig. 16B, Pax-5 activates the CD23a core 
promoter (pLuc+ACP) about 7 fold when compared with the activity of the promoter without 
Pax-5. This is in line with our hypothesis that the CD23-1 binding site behaves as a 
functional Pax-5 site. 
By site directed mutagenesis, we have mutated the CD23-1 putative binding site within the 
pLuc+ACP vector. The mutant construct, named pLuc+ACPmu contains the same nucleotide 
substitutions as the oligonucleotide CD23-1mu1 (Fig. 14A). The pLuc+ACPmu construct 
containing the CD23a core promoter with the mutated Pax-5 binding site failed to activate as 
strongly as the pLuc+ACP contruct containing the wild-type promoter. The remaining 
activation may be due to the recruitment of Pax-5 into protein complexes that can bind with 
lower efficiency but can still lead to a slight activation of the promoter.  
A recent study [21] identified IL-4 as the main activator of the CD23a promoter, whereas the 
CD23b promoter shows a much wider range of responsiveness to extracellular stimuli. The 
authors described two STAT6 binding sites located close to each other in the –500 to -350 
region of the CD23a promoter. Therefore we investigated if Pax-5, besides controlling the 
specificity of CD23a expression in B-cells, also cooperates with STAT6 in inducing a strong 
expression of the isoform.  
For this purpose, another luciferase reporter construct (pLuc+AP) that includes these STAT6 
binding sites was made by cloninig the whole CD23a promoter (from position –1216 to 
position +211) into the pLuc+ vector (Fig. 16A). pcDNA3-Pax-5 and pXM-STAT6 were used 
for ectopic expression of Pax-5 and STAT6 respectively in 293 cells. As shown in Fig. 16B, 
Pax-5 and STAT6 each induced an 11-14-fold activation of the CD23a promoter 
respectively. When the cells are co-transfected with both transcription factors, however, a 40-
fold activation of the CD23a promoter is induced. These results suggest that Pax-5 not only 
stimulates CD23a expression, but also cooperates with STAT6 in enhancing the level of 
CD23a transcription. 
 
1.6 Pax-5 mediates CD23a expression in vivo  
 
In order to further investigate whether the B-cell restricted expression pattern of CD23a is 
determined by lineage specific Pax-5 expression in vivo we used the monocytic cell line U-
937 to determine the effects of ectopic Pax-5 expression on CD23a induction. U-937 cells, 
like other myeloid cells, regularly express only CD23b after appropriate stimulation with IL-
4. 
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Human Pax-5 cDNA was stably inserted into the genome of U-937 cells by means of the 
recombinant retrovirus pEGZ [47]. The Pax-5 protein was coordinately expressed with the 
chimeric selection marker composed of the enhanced green fluorescent protein (EGFP) and 
the Zeocin (Zeo) resistance protein. We isolated a Pax-5 expressing population (U-937/EGZ 
Pax-5) using Zeo selection. As a control, we generated populations expressing only the 
selection marker at equivalent levels (U-937/EGZ). Western Blot analysis of protein extracts 
from Pax-5 transfected U-937 cells showed positive Pax-5 protein expression with a band 
located around 40 kDa (Fig. 17B). In addition we verified the correct transduction of the Pax-
5 gene by sequencing. The full length Pax-5 gene was successfully integrated in the U-937 
genome without deletions or point mutations (data not shown). The smaller size of the Pax-5 
expressed in U-937 cells might be due to splicing differences. 
Since available anti-CD23 antibodies are directed against the extracellular region of the 
receptor, which is shared between the two isoforms, the expression of CD23a cannot be 
analysed by FACS staining or Western Blot analyses. Therefore we performed RNase 
protection assays using a single RNA probe that is fully homologue to the CD23a mRNA 
and 2/3 homologue to CD23b mRNA. The analysis within one sample allows a reliable 
quantification of CD23a and CD23b isoforms on the transcriptional level. 
Fig. 17A shows the results of the RNase protection assay performed with RNA extracts from 
U-937 cells, U-937 expressing only the selection marker EGZ and U-937 transfected with 
Pax-5. RNA extracts from WIL2 cells (B-cell line) were used as control for CD23a 
expression. CD23a/b isoforms expression was assessed under non-stimulating conditions, as 
well as after 48 hours stimulation with IL-4, PMA and IL-4+PMA. 
As expected, IL-4 and PMA stimulations alone induce readily detectable amounts of CD23b 
mRNA in U-937, U-937/EGZ and U-937/ Pax-5 cells (Fig. 17A, lanes 2-3, 6-7 and 10-11). 
CD23b expression was further increased when cells were stimulated with a combination of 
the two stimuli (PMA and IL-4).  
However, most importantly, U-937 cells transduced with Pax-5 exibited a strong and 
reproducible expression of CD23a mRNA when stimulated with PMA plus IL-4 (Fig. 17A, 
lane 12). IL-4 alone, as well as PMA stimulation alone were unable to induce CD23a 
expression in this monocytic cell line, providing evidence that other factors are required 
together with Pax-5. This experiment provides strong evidence that Pax-5 may be a limiting 
factor for enabling CD23a expression in vivo.  
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Fig.17 CD23a is expressed in U-937 cells transduced with Pax-5. (A) RNase protection assays
were performed with RNA extracts from wild-type U-937 cells (lanes 1-4), U-937 transfected 
with  the selection marker EGZ (lanes 5-8) and U-937 transfected with Pax-5 (lanes 9-12). Cells
were stimulated with 50ng/ml IL-4 and 3ng/ml PMA for 48h as indicated. WIL2 cells (B cell 
line) express CD23a and CD23b constitutively and were used as controls (lanes 13-14). The 
extracted RNA was hybridized with a single CD23 mRNA probe for both CD23a and CD23b
i s o f o r m s .  ( B )  We s t e r n  B l o t  a n a l y s i s  t o  a s s e s s  P a x - 5  e x p r e s s i o n .
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2. Using a Two Hybrid System to find a cytoplasmic interaction partner 
for the CD23 receptor  
 
 
 
The question of the transduction pathways involved in CD23 signalling is one of great 
importance since CD23 plays important roles in several diseases. No direct interaction 
partners for the cytoplasmic domain of membrane receptor CD23 have been found till now. 
We used a yeast two-hybrid system to address this question since it provides a powerful 
technique to screen large libraries of genes and identify new protein-protein interactions 
within the cell. 
 
2.1 Establishing the system 
 
The CytoTrap Two Hybrid System (Stratagene) is based on generating fusion proteins 
whose interaction in the yeast cytoplasm induces cell growth by activating the Ras signaling 
pathway. 
 
2.1.1 Bait constructs 
pSos functions as bait vector by cloning the gene of interest -here CD23- in the MCS of the 
plasmid (Fig.18). 60-63 bp long synthetic oligonucleotides incoding for the 21-20 amino 
acids of the CD23a and CD23b intracytoplasmic tails were cloned in the MCS of the pSos 
vector. These constructs, named pSosCD23a and pSosCD23b, express CD23a and CD23b 
cytoplasmic domains as fusion proteins to the C-terminal part of human SOS protein. 
pMyr functions as target vector. In order to screen for an interaction partner for CD23 a 
human spleen library cloned in the pMyr vector was purchased from Stratagene (Fig.18). 
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Fig.18 Schematic diagram of the bait and target constructs used in the CytoTrap Two Hybrid 
System 
 
 
  
2.1.2 Phenotype control 
In order to verify the mutant phenotype, the yeast strain cdc25H was tested for its ability to 
grow on reach media (YPAD-Yeast extract, Peptone, Dextrose medium) and on dropout 
media, as presented in Table 1: 
 
Table.1 
Strain          YPAD        Glucose(-Ura, -Leu)     Galactose(-Ura,-Leu)                          
25°C           37°C                 25°C    37°C                     25°C      37°C 
cdc25H    +                 -           -                     -                          -                  - 
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 2.1.3 Control reactions 
In order to test the reliability of the system, the pSos-bait constructs and the control plasmids 
were co-transformed in pairwise combinations into the cdc25H strain, plated on selective 
media and assayed for growth at 37°C and 25°C. The results are presented in the following 
table. Expression of the pMyr fusion protein is induced by adding galactose to the growth 
media and repressed by glucose. 
 
Table.2 
 Control plasmids      SD(-Ura,-Leu)/25°C      SD(-Ura,-Leu)/37°C 
Sos fusion       Myr fusion Glucose  Galactose      Glucose Galactose 
MAFB        MAFB       +           +             -        + 
Collagenase       MAFB       +           +             -         - 
MAFB        Lamin C       +           +             -         - 
CD23a        Lamin C       +           +             -         - 
CD23b        Lamin C       +           +             -         -  
 
The transformation of pSosCD23a/b with pMyrLamC verifies that the constructs do not 
interact with the myristilation signal of the target fusion protein. The test of the control 
plasmids was permanently used during the screening and checking of the upcoming 
interactions as a control of the reliability of the system.  
 
 2.1.4 Establishing a high efficiency transformation protocol 
Another important point to establish an efficient Two Hybrid System screening was to 
obtain a high efficiency of transformation in cdc25H yeast strain. Using the protocol 
described in Materials and Methods plasmid transformation in this yeast strain achieved 
efficiencies of 5000 to10 000 colonies per plate (150 mm diameter). 
 
2.2 Screening results with pSosCD23a and pSosCD23b 
 
The screening procedure is described in Material and Methods. 
The two constructs described above (pSosCD23a and pSosCD23b) were used to screen the 
human spleen library cloned in the pMyr vector. The results are presented in Table 3. 
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Table.3 
 
Two Hybrid System Screen     CD23a  CD23b 
 
Number of clones screened     1,1 x 106  7 x 105 
 
Number of clones growing on     
SD galactose (-Ura, -Leu) at 37°C        305     518 
(possible “temperature revertants”) 
 
Number of “putative positive” clones       17      34 
 
Number of “true positive“ clones         -     - 
 
 
 
More than 1 million clones have been screened with the pSosCD23a construct and 
aproximatively 700 000 clones with the pSosCD23b construct.  305 and 518 clones for the 
CD23a or CD23b screening respectively were growing at 37°C on galactose medium after 
the replica plating step. Each of these colonies was individualy tested for the temperature 
revertant phenotype. Roughly 95 % of them have lost the point mutation and only ~5% of 
them hosted a real interaction. The 17 clones identified in the CD23a screening and the 34 
clones identified in the CD23b screening were all tested in order to see if they are “true 
positive”- they host an interaction between a library protein and the bait (CD23), or they are 
“false positive” –they host an interaction between a library protein and the fusion protein 
(human SOS). In order to make the distinction, the library clones were retransformed in 
yeasts together with the pSos vector, a construct that only express the human SOS protein, 
without the CD23 bait (Fig.11). In all cases, the resulting colonies maintained the ability to 
grow on selective galactose media at 37°C. That showed that human SOS fusion protein, 
instead of the bait protein (CD23) was involved in all interactions. All clones resulted in the 
screening were considered “false positives”. 
False positive clones are an intrinsic of the system, as SOS is an adaptor molecule and it will 
interact with a large number of proteins encoded by the human spleen library.  
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SD Glucose (-Leu,-Ura)
25°C
SD Galactose (-Leu,-Ura)
37°C
SD Glucose(-Leu,-Ura)
37°C
Fig.19 Selecting the „putative positive“ clones. (A) Growing the transformants at 37°C, on 
Galactose medium allows selection of clones that host an interaction. (B) Growing the
transformants on Glucose medium at 37°C checks the „temperature revertant“ phenotype. (C) 
Growing the transformants on Glucose medium at 25°C provides the back up for further analyses.
A B C
 
 
On the other hand, using SOS as a fusion protein could mask interactions between CD23 
and i.e. small G proteins, because these could bind to SOS directly. As we had obtained 
quite a big number of false positive clones, we decided to check this hypothesis by using a 
two-hybrid system based on a different principle. 
 
2.3 Using the MATCHMAKER GAL4 Two-Hybrid System to verify the screening 
results 
 
This system is a GAL4- based two-hybrid that provides a transcriptional assay for detecting 
protein interactions in vivo in yeasts. 
 
2.3.1 Establishing the system 
a) Bait and target constructs 
CD23 was cloned in the MCS of the pGBKT7 plasmid. 60-63 bp long synthetic 
oligonucleotides incoding for the 21-20 amino acids of the CD23a and CD23b 
intracytoplasmic tails were cloned between the NcoI and BamHI sites of the vector. The 
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constructs would express CD23a and CD23b cytoplasmic domains as fusion proteins with 
GAL4 DNA-BD. 
Screening with the CytoTrap Two-Hybrid System resulted in a total of 17 clones when 
CD23a was used as bait and 34 clones when CD23b was used as bait. There was a high 
probability that certain genes of the library came up more than once in the screening process 
and that a certain number of duplicates would be found in the total of 51 clones. 
In consequence, they were subjected to restriction enzyme analyses with HpaII, an enzyme 
that cuts CCGG motifs. The digest profile was used to compare and clasify the clones 
(Fig.20). The 51 clones resulted in 12 distinct profiles representing distinct genes. These 
genes were then cloned between the EcoRI and XhoI sites of the pGADT7 plasmid. The 
constructs, named pGADT7-1/12, would express them as fusion proteins with GAL4 DNA-
AD. 
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Fig.20 HpaII digest of false positive clones resulted from the Cytotrap Two Hybrid System 
screen 
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b) Control of the yeast phenotype 
In order to verify the phenotypes, the two yeast strains provided by the system were tested 
on dropout media as follows. 
 
 
Table.4 
 
Strain      SD/-Ade      SD/-Met      SD/-Trp      SD/-Leu      SD/-His      SD/-Ura      YPDA 
 
AH109         -                    +     -             -         -          -       + 
Y187          -                    -     -  -         -          -       + 
 
 
 
c) Control reactions 
In order to test the general reliability of the system and if DNA-BD and AD fusion 
constructs do not autonomously activate reporter genes, the pGBKT7-CD23a/b constructs, 
pGADT7-1/12 and the control plasmids were co-transformed in various combinations into 
the AH109 strain, plated on selective media and assayed for growth and blue/white 
phenotypes. The results are presented in the Table 5. 
These results also show how one can modulate the stringency of the screening by plating the 
transformants on different selective media. The use of high-stringency media, SD/-Ade/-
His-Leu/-Trp/X-α-Gal, virtually eliminates false positive interaction. The use of low-
stringency media, SD/-Leu/-Trp, favours the detection of weak or transient interactions. 
Also, the independent transformation of pGBKT7-CD23a/b and pGADT7-1/12 into AH109 
verifies that the constructs do not activate reporter genes by themselves. 
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Table.5 
 
Vectors   SD Minimal Medium    Phenotype 
         Mel1/lacZ    His/Ade 
pCL1    -Leu/X-α-Gal    Blue           + 
pGADT7   -Leu     White           + 
pGBKT7-53   -Trp     White           + 
pGADT7 + pGBKT7-53 -Leu/-Trp    White           + 
    -Leu/-Trp/ X-α-Gal   Blue           + 
-Ade/-His-Leu/-Trp   White           + 
-Ade/-His-Leu/-Trp/X-α-Gal  Blue           + 
 
pGADT7   -Leu     White            + 
pGBKT7-Lam   -Trp     White            + 
pGADT7 + pGBKT7-Lam -Leu/-Trp    White            + 
    -Leu/-Trp/ X-α-Gal   White            + 
-Ade/-His-Leu/-Trp                - 
-Ade/-His-Leu/-Trp/X-α-Gal               - 
pGBKT7-CD23a/b  -Trp     White            + 
    -Trp/ X-α-Gal    White            + 
pGADT7-1/12   -Leu     White            + 
    -Leu/ X-α-Gal    White            + 
 
 
 
 
2.3.2 Results of the testing 
Finally, pGBKT7-CD23a and pGBKT7-CD23b were separately cotransformed with each of 
the pGADT7-1 to pGADT7-12 constructs. In order to detect a plausible interaction, medium 
and low-stringency media were used. The results are presented in the following table.  
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Table.6 
 
Vectors         SD Minimal Medium     Phenotype 
             Mel1/lacZ    His/Ade 
pGBKT7-CD23a + pGADT7-1/12      -Leu/-Trp        White         + 
                   -Leu/-Trp/ X-α-Gal      White         + 
 -His/-Leu/-Trp             -          
 -His/-Leu/-Trp/ X-α-Gal            - 
pGBKT7-CD23b + pGADT7-1/12      -Leu/-Trp        White          + 
                         -Leu/-Trp/ X-α-Gal      White          + 
 -His/-Leu/-Trp             -          
 -His/-Leu/-Trp/ X-α-Gal            - 
 
Testing the interaction into the MATCHMAKER system verified that there was no true 
interaction between CD23 cytoplasmic tail and the clones resulted in the CytoTrap 
screening. 
 
2.4 New constructs for the CytoTrap Two Hybrid System bait vectors 
 
The fact that CD23 was cloned in the MCS of the pSos vector caused the intracytoplasmic 
part of CD23 to be expressed at the carboxyterminal end of SOS, implying also that the free 
end of CD23 was the C-terminal end. However, CD23 is a type II receptor, with the N-
terminal end into the cell.  
In order to change the orientation of the bait in the fusion protein we decided to clone 
CD23a/b upstream of the hSOS gene. This new constructs would express the bait at the N 
terminal end of human SOS protein implying the same orientation for the cytoplasmic tails 
of CD23a and CD23b as it occurs in vivo (Fig.21). 
In addition, there is also a considerable difference in size between the human SOS proteins, 
which is a multidomain adaptor protein of 170 kDa and the short cytoplasmic tail of CD23, 
which has a total of 20-21 amino acids.  In order to make this small amino acid tail more 
obvious into the fusion protein, we considered using a linker region.  A 15 amino acids long 
synthetic hinge region containing a glycine and serine repetitive motif was used as linker 
between CD23a/b and the SOS protein. The amino acid sequence of this flexible 
oligopeptide is presented in the Fig. 21B. 
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MNPPSQ EIEELPRRRCCRhSOSN C
C
CD23
A
GGGGSGGGGSGGGGSMNPPSQ EIEELPRRRCCR hSOS
N CN
LinkerCD23
B
Hind III Xba I Sma I Start                          BamH I         Nco I        Srf I                         Sal I   
5’ CCA AGC TTC TAG ACC CGG GGG CAC C ATG CAG hSOS ATT AGT TAT AGT AGG ATC CCC ATG GCC CGG GCG ACG
3’ GGT TCG AAG ATC TGG GCC CCC GTG G TAC GTC            TAA TCA ATA TCA TCC TAG GGG TAC CGG GCC CGC TGC 
BssH II            Mlu I              Sac I              Not I  Sac II 2 x Pac I
TCG ACG CGC GCA CGC GTG AGC TCG CGG CCG CCG CGG TTA  ATT  AAT  TAA  TTA  ACC GCG  3’
AGC TGC GCG CGT GCG CAC TCG AGC GCC GGC GGC GCC AAT  TAA TTA  ATT  AAT  TGG CGC  5’
CD23a/b + Linker
MCS
C
 
 
 
 
 
Fig.21 Schematic representation of the CD23-SOS fusion proteins expressed as bait in the 
CytoTrap Two Hybrid System. (A) The pSosCD23 construct expresses the cytoplasmic domain of 
CD23 receptor at the C terminal end of human SOS. (B) The pSosCD23+Linker construct expresses 
the CD23 cytoplasmic domain at the N terminal end of human SOS. A synthetic linker region is 
interposed between the two proteins. (C) In the pSosCD23+Linker construct the DNA encoding the 
cytoplasmic domain of CD23 and a linker region were cloned in a unique HindIII site located 
upstream of the hSOS gene. 
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Fig.22 CD23-SOS fusion protein is expressed in the yeast cytoplasm. Protein extracts from 
yeasts transformed with pSos, pSosCD23a+Linker and pSosCD23b+Linker constructs were analysed 
by Western Blot using an anti-hSOS antibody. 
 
 
Synthetic oligonucleotides representing the cytoplasmic tails of the two CD23 isoforms and 
the linker region were cloned into a Hind III unique restriction site situated 20 bases 
upstream of the starting point of SOS. The oligonucleotides were designed to contain a new 
START codon, a Kozak sequence in front of the START codon and restriction enzyme sites 
that would allow cloning without causing a frameshift in the hSOS gene located now 
downstream of the bait gene. The new constructs were named pSosCD23a+Linker and 
pSosCD23b+Linker.  
In order to verify the expression of the fusion protein in the yeast cytoplasm, Western Blot 
analyses were performed using yeast lysates. As none of the available anti-CD23 antibodies 
work in Western Blot analyses, we used an anti-human SOS antibody to assess the 
expression of the fusion protein. As shown in Fig. 22, the CD23-linker-human SOS fusion 
protein was expressed in the yeast cytoplasm. 
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2.5 Screening results with pSosCD23a+Linker and pSosCD23b+Linker 
 
These new bait constructs (pSosCD23a+Linker and pSosCD23b+Linker) were used to 
screen again the human spleen library cloned in the pMyr vector. The results are presented 
in Table 7. 
 
Table.7 
 
Two Hybrid System Screen     CD23a  CD23b 
 
 
Number of clones screened     5,8 x 105  3,5 x 105 
 
 
Number of clones growing on     
SD galactose (-Ura, -Leu) at 37°C        344     464 
(possible “temperature revertants”) 
 
 
Number of “putative positive” clones       14      13 
 
 
Number of “true positive“ clones         -     - 
 
 
Around half a million clones have been screened with each of the pSosCD23a+Linker and 
pSosCD23b+Linker constructs. 278 and 391 clones for the CD23a or CD23b screening 
respectively were growing at 37°C on galactose medium after replica plating step. Each of 
these colonies was individually tested for the temperature revertant phenotype. Roughly 95-
97 % of them have lost the point mutation and only ~5% of them hosted a real interaction. 
However, the 27 clones identified for CD23a and CD23b screening were all “false positive” 
since they interact with human SOS. 
 
2.6 New construct for the CytoTrap Two Hybrid System CD23a bait vector 
 
One known problem of yeast two hybrid systems for finding protein-protein interactions is 
that, if these interactions require phosphorylation in mammalian cells, they will not be 
detected. Yeast hosts might not express the kinases or they might not have the same 
phosphorylation patterns as the mammalian kinases.  
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The tyrosine residue in position 6 of the CD23a cytoplasmic tail could be a key player in 
recruiting other signalling molecules. The lack of phosphorylation at this site could have 
been a major problem for detecting an interaction. In consequence, we considered replacing 
the tyrosine residue with a glutamic acid residue. This strategy can be used in experimental 
settings when tyrosine phosphorylation cannot be achieved, as glutamic acid can mimic 
phosphorylated tyrosine in certain situations. 
By site directed mutagenesis, using pSosCD23a+Linker as template, we constructed a new 
bait vector, named pSosCD23a-Glu. This new construct also contains the CD23a cytoplasmic 
tail expressed at the N-terminal part of human SOS and the linker between the two fusion 
proteins. In addition, the tyrosine from position 6 of the cytoplasmic tail of CD23a was 
replaced with a glutamic acid residue. 
The pSosCD23a-Glu will be used in future screenings. 
 
2.7 Verifying interactions between two known proteins 
 
The CytoTrap Two Hybrid System can also be used to verify interactions between two 
known proteins. p59fyn (a member of the src family of protein kinases) was claimed to 
associate with the product of a transfected CD23 gene in a NK cell line.  
In order to verify if this interaction can be detected and reproduced in the CytoTrap two-
hybrid system, fyn cDNA amplified by RT-PCR from B-cell total RNA was cloned in the 
pMyr vector. pSosCD23a+Linker, pSosCD23b+Linker and pSosCD23a-Glu were co-
transformed with pMyrfyn. There was no detectable interaction between the two proteins in 
the environment provided by the CytoTrap two-hybrid system (Table 8). 
 
Table.8 
 
 Plasmids          SD(-Ura,-Leu)/25°C       SD(-Ura,-Leu)/37°C 
pSos                  pMyr  Glucose  Galactose    Glucose Galactose 
Coll        fyn        +           +   -  - 
CD23a+Linker      fyn      +           +   -             - 
CD23b+Linker      fyn                     +           +   -             - 
CD23a-Glu       fyn           +                            +   -  - 
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2.8 Perspectives 
 
pSosCD23a-Glu represents a bait construct substantially improved. It has the advantage to 
express CD23 cytoplasmic tail as it occurs in vivo, with the N-terminus free as bait and 
contains a glutamic acid residue that can substitute a phosphorylated tyrosine in position 6. 
Using this construct for screening an improved potential to find an interaction partner for the 
CD23 receptor is to be expected.  
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DISCUSSION 
 
 
High CD23 expression is associated with various chronic diseases such as B-CLL, 
rheumatoid arthritis and lupus erythematosus. It is assumed that signalling through CD23 
contributes to the pathogenesis of these diseases. In humans there are two CD23 isoforms 
that are differentially expressed. Whereas CD23b is widely detected on lymphocytes and 
myeloid cells, CD23a is restricted to B-lymphocytes. The isoforms differ only in the short 
amino terminal intracytoplasmic part [87] and seem to be connected to different signal 
transduction pathways. The CD23a isoform specifically mediates endocytosis of bound 
ligands and can therefore influence B-cell mediated antigen presentation [41]. CD23b was 
shown to be associated with phagocytosis of IgE coated-particles [88].  
 
Distinct promoters regulate the two CD23 isoforms expressed in humans. So far, IL-4 has 
been described as being the most important activator of CD23a and CD23b expression and 
binding sites for STAT6 have been characterized in both promoters. [21,41,87]. In addition 
to the IL-4 responsive element, NF-AT binding sites have been characterized in the CD23b 
promoter [40]. There are very limited data concerning the regulation of the human CD23a 
promoter. Studies of the mouse CD23 promoter, which is closely related in sequence to the 
human CD23a promoter, revealed functional STAT6, NF-kB and C/EBP binding sites [82]. 
Since the mouse and human CD23a promoter are 72% homologous in the core region, most 
of the binding motifs in the human promoter were characterized by comparison with the 
mouse promoter. Richards et al [65] observed that the homologous nucleotides appear in 
clusters, suggesting that common response elements have been conserved in the two 
promoters. As shown in Fig. 10A, STAT6, NF-kB and C/EBP binding sites are localized in 
the –70 to –140 region of the CD23a core promoter. Additional STAT6 binding sites were 
characterized in the extended CD23a promoter, in the –300 to –500 region. Multimerized 
STAT6 binding sites, as well as their association with NF-kB sites, seem to be a common 
trait of IL-4 regulated promoters [14, 54]. In addition, EBNA2 and Notch-2 can regulate the 
CD23a promoter by binding to CBF1 sites [32,48]. Both activatory elements may play a role 
in the immortalisation of the B-cell by enhancing CD23a expression.   
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The question of how the B-cell specific expression of CD23a isoform is regulated has not 
been experimentally addressed so far. Among B-cell specific transcription factors, Pax-
5/BSAP binding sites have been very recently predicted in the CD23a core promoter [21,32]. 
Pax-5 is a critical modulator of early B-cell differentiation. Its expression is restricted to B 
cells, embryonic brain and testis. Binding sites for Pax-5 have been identified in promoters of 
several genes. While being a positive regulator of CD19, mb-1 and RAG-2 [39,43,59] Pax-5 
acts as a repressor for the immunoglobulin heavy-chain 3’C∝ enhancer and the J-chain 
[66,75]. The importance of Pax-5 for development was demonstrated by knock-out 
experiments. Pax-5 is important in early and late B-cell development. Most of Pax-5-/- mice 
die within 3 weeks and B-cell development is blocked at the pro-B-cell stage [84]. The loss 
of Pax-5 in mature B-cells severely impairs B-cell identity [31]. 
Here we demonstrate the presence of a functional Pax-5 binding site in the CD23a core 
promoter that is able to induce and enhance CD23a expression. We also advance the 
hypothesis that Pax-5, being a B-cell specific protein, plays a central role in regulating the 
specific expression of CD23a on B-cells. CD23 is expressed later in the B-cell development 
than Pax-5. Additional transcription factors must be involved in modulating CD23a 
expression. The association of Pax-5 with other transcription factors in regulatory complexes 
has been documented so far. For example, Pax-5 associates with Oct-1 (octamer binding 
proteins) and NF-kB in modulating the 3’α-hs4, a distal 3’ enhancer that regulates the IgH 
gene cluster at multiple stages of B-cell development. While Oct-1 and kB act as positive 
regulators at all stages of differentiation, Pax-5 acts as a repressor at the pre-B-cell stage and 
as a positive regulator in mature B-cells [52, 53]. Furthermore, both CD23 and Pax-5 
expression are lost when differentiation to plasma cells occurs. This is in line with Pax-5 
being a prerequisite factor for CD23a expression. 
Another interesting observation comes from the comparison of the CD23 promoter with the 
germline immunoglobulin Cε and Cγ1 promoters, which are also regulated by IL-4. The 
transcription of these germline immunoglobulin genes is necessary for class switching to IgE 
and IgG1. Different combinations of cytokines and mitogens have been shown to stimulate 
class switching to particular isotypes. IL-4 promotes a class switch from IgM to IgE and 
IgG1 and STAT6 binding sites have been identified in both ε and γ1 germline genes. In 
addition, NF-kB and C/EBP binding sites have been described [14], while Pax-5 was shown 
to bind close to the STAT6 site in the germline ε promoter. Studies by Liao et al. show that 
Pax-5 is essential for germline ε transcription and therefore essential for class switching and 
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IgE production [46]. Thus, it seems that an IL-4 response in B-cells involves the cooperation 
of at least four transcription factors: C/EBP, STAT6, NF-kB and Pax-5. A high degree of 
sequence homology exists between the CD23 and germline ε promoters in both human and 
mouse [65]. This high homology in the promoter sequences is also reflected by the fact that 
both CD23 and IgE are upregulated by IL-4 in combination with LPS or anti-CD40. Since 
C/EBP, STAT6, NF-kB binding sites have been described in the CD23 promoter [82, 65], we 
were interested to verify if CD23a, as an IL-4 responsive promoter, is Pax-5 sensitive. 
The identification of putative binding sites for Pax-5 in the CD23a core promoter was 
initially done by sequence alignment with the Pax-5 consensus sequence. This consensus 
motif has been characterized by Czerny et al. in an extended comparison between natural 
targets of Pax-5, including the recognition sequence which originates from the sea urchin 
H2A-2.2 gene and the human CD19 gene [12]. As seen in Fig. 1B, the Pax-5 recognition 
sequence is divided in two halves – a more extensive 3’-consensus motif recognized by the 
amino-terminal subdomain of the paired domain and a 5’-consensus motif recognized by the 
carboxy terminal part of the paired domain. One important observation was that all naturally 
occurring binding sites identified so far deviate from the consensus sequence and that Pax-5 
is able to interact with a panel of seemingly degenerate recognition sequences. In testing the 
Pax-5 binding sites, we considered all putative binding sites with at least 50% identity to the 
consensus sequence. This resulted in three putative Pax-5 binding sites, which we designated 
as CD23-1, CD23-2 and CD23-3. 
The putative binding site CD23-1 was the only one able to compete the high affinity H2A-2.2 
binding site and to directly bind the Pax-5 protein (Fig. 11). This was further confirmed by 
the fact that oligonucleotides containing a mutated CD23-1 binding site completely lost the 
ability to bind the Pax-5 protein (Fig. 12). Interestingly, a gap had to be introduced in the 
CD23-1 binding site in order to reconstitute the symmetry of the site (Fig. 10B). Another 
putative binding site (CD23-3), which had 89% homology to the consensus sequence failed 
to bind Pax-5 in the same assays (Fig. 11). These observations confirm the difficulty to 
predict Pax-5 binding sites using sequence comparison alone. It appears that all naturally 
occurring binding sites identified so far deviate from the consensus sequence by base 
changes in their 5’ or 3’ half sites. In consequence, Pax-5 protein possesses a high flexibility 
to recognize quite degenerate recognition sequences as a result of the bipartite structure of 
the paired domain. Furthermore, binding sites with a complete match to the consensus 
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sequence would possess an exceptionally high affinity for Pax-5, which apparently is not 
required in vivo.  
Another approach to identify Pax-5 binding sites in the CD23a core promoter was to 
construct overlapping oligonucleotides covering the whole length of the promoter and to test 
their ability to compete the sea urchin H2A-2.2 binding site in EMSAs. Both strategies 
revealed CD23-1 as the only site in the CD23a core promoter able to bind directly the Pax-5 
protein (Fig. 13). 
It is interesting to note that in our hands none of the two Pax-5 sites predicted in a recent 
study by Hubmann et al. [32] interacts directly with the Pax-5 protein. As this study used 
nuclear extract from B-CLL cells, it is possible that Pax-5 was recruited by another factor 
into a protein complex, which interacts with these putative sites. 
To test the function of the identified Pax-5 binding site in vitro we performed luciferase 
assays in 293 cells linking the CD23a core promoter or an extended CD23a promoter to a 
luciferase reporter gene. We chose this approach since previous work has shown that 
promoters of Pax-5 regulated genes, like CD19, are weakly active in transiently transfected 
B-cells and can only be stimulated by ectopic Pax-5 expression in heterologous cell types [9]. 
Overexpression of Pax-5 in 293 cells led to a 7-10 fold activation of both CD23a promoter 
constructs (Fig. 14). However, reporter constructs with the mutated CD23-1 site were still 
slightly active. The remaining activation may be due to the recruitment of Pax-5 into protein 
complexes that can bind with lower efficiency but can still lead to a slight activation of the 
promoter. This may be indeed another mechanism by which Pax-5 regulates the CD23a 
promoter and which needs to be approached in future studies. Furthermore, in experiments 
using the extended promoter which includes two reported STAT6 sites, Pax-5 acted together 
with STAT6 in further enhancing CD23a expression above the level of the induction 
provided by the two factors alone. These results suggest that Pax-5 not only determines the 
B-cell specificity of CD23a, but also potentiates the STAT6 mediated stimulatory effect.  
Previous studies seem to lead to the scenario that STAT6, even when multimerized, is not 
sufficient for the induction of IL-4 regulated genes [14, 54]. The cooperation of other 
transcriptional activators, like NF-kB, appears to be necessary, for example, in order to 
activate the transcription of the germline Cε promoter. The interaction with NF-kB appears to 
enhance the DNA binding affinity and the transactivating affinity of STAT6 [74]. It may also 
be possible that Pax-5 synergically acts and perhaps also directly associates with STAT6 
(and NF-kB) in order to activate the CD23a promoter. 
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To further investigate the ability of Pax-5 to induce CD23a expression in vivo, we selected 
the monocytic cell line U-937, which normally expresses only CD23b after appropriate 
stimulation [87]. Using a retroviral infection system we ectopically expressed Pax-5 in U-937 
cells. Western Blot analyses demonstrated a strong expression of Pax-5 with a band located 
around 40 kDa (Fig. 15B). The B cell line WIL2 used as a CD23a positive control showed a 
Pax-5 band located around 45 kDa, somewhat lower than the expected 53kDa. As sequence 
analyses of the integrated Pax-5 construct revealed no partial deletions or point mutations 
creating a STOP codon we suppose that the size difference is due to splicing differences or 
post-translational modifications. Zwollo et al. described several Pax-5 isoforms expressed in 
different pro-, pre- and mature B-cell lines. They are generated by the usage of a second 
distal start codon located downstream of exon 1 or by differential splicing. The expression of 
these isoforms seems to vary during B-cell development whereas the standard Pax-5 isoform 
is stably and relatively highly expressed at all B-cell stages. Their function is not yet 
characterized, but they seem to retain their capacity to interact with Pax-5 binding sites or to 
interact with other regulatory factors necessary for initiation of transcription [90]. 
The expression of Pax-5 in the U-937 cell line enabled a clear CD23a expression after 
appropriate stimulation with IL-4 and PMA. In comparison to B-cells, where the ratio of 
CD23a: CD23b expression is around 3-4:1 independent of the applied stimulus [25], CD23b 
exceeds CD23a expression in U-937/Pax-5 cells. This is likely due to the difference in the 
cellular environment between B-cells and macrophages. The U-937 cells have the phenotype 
of a mature, fully differentiated macrophage. One can expect different conditions compared 
to a B-cell, like the availability of the promoter or the presence of specific transcription 
factors. In any case, the CD23a induction in Pax-5 transduced U-937 cells was consistent and 
highly reproducible. Neither IL-4 nor PMA stimulation alone were able to induce CD23a 
expression in Pax-5 transfected U-937 cells. This would indicate IL-4 as being necessary but 
not sufficient for Pax-5 mediated expression of the CD23a isoform. Pax-5 seems to be a 
prerequisite transcriptional activator, which cooperates with other transcription factors during 
B-cells specific expression of the CD23a isoform. 
In conclusion, we identified a functional Pax-5 binding site within the CD23a core promoter. 
In combination with other transcription factors, Pax-5 is able to mediate CD23a expression 
even in cells that normally do not express CD23a. Therefore our results indicate Pax-5 being 
a key regulator of B-cell specific expression of CD23a. 
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The question of the transduction pathways involved in CD23 signaling is one of great 
interest as CD23 plays important roles in several diseases. In B-CLL, for example, CD23a 
expression is associated with a state of cell survival. In contrast to normal B-cells where after 
24 hours of incubation CD23a transcription is completely lost, accompanied also by a down-
modulation of the antiapoptotic gene bcl-2, the levels of CD23a and bcl-2 expression remain 
high in B-CLL cells [32]. Overexpression of CD23a is associated with enhanced cell 
viability.  
The two isoforms have different expression patterns and apparently quite distinct functions. 
Comparison between the events taking place in cells that express only one or both isoforms 
seem also to lead to the idea of different signal transduction pathways for CD23a and CD23b. 
Studies done by Kolb and co-workers show that cross-linking of CD23 on B-cells provokes a 
rapid increase in Ca2+ resulted from inositol (1,4,5) triphosphate generation and a slow 
accumulation of cAMP. Ligation of CD23 on the surface of monocytes results in cAMP 
generation and is additionally coupled with activation of iNOS. The difference is most likely 
due to the 6-7 amino acids at the N-terminal end of the cytoplasmic tail.   
CD23a only contains a Tyr residue in position 6 and a Ser residue in position 7 that are 
predicted sites for phosphorylation. The tyrosine in CD23a cytoplasmic tail exists as a 
member of the YSEI sequence. The YXXL sequence is known as an ITIM motif, and if Leu 
can substitute for Ile, than theYSEI in the human CD23a could be seen as a variant of an 
ITIM motif [36]. As the suppression of IgE production was released in CD23-knockout mice, 
it would be reasonable to suppose that CD23 contains an inhibitory signal within the 
molecule. The meaning of this sequence remains unclear, although it may provide a base for 
the difference in signalling between the two isoforms. 
Our approach to address the question of the transduction pathways involved was to look for 
direct interaction partners for CD23. Preliminary data suggested that a pertussis toxin-
insensitive G protein couples membrane CD23 to the PLC. It is also possible that a protein 
tyrosine kinase is involved, since the product of the transfected CD23 gene in a NK cell line 
was found associated with p59fyn [78].  
We used a yeast two-hybrid system to look for interaction partners for the CD23 receptor. 
These systems provide a powerful technique to screen large libraries of genes and to identify 
new protein-protein interactions within the cell. When compared with more traditional 
methods for studying protein-protein interactions, the two-hybrid system seems to offer 
several advantages. As the interaction occurs in vivo, the need for the detailed and laborious 
manipulation of conditions necessary for in vitro biochemical binding assays is abrogated. 
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Also, in at least some cases, the two-hybrid system is more sensitive than co-
immunoprecipitation in detecting weak interactions. The system we employed –the 
CytoTrap Two Hybrid System from Stratagene- offers additional advantages over the 
traditional two hybrid systems. As the interaction takes place in the cytoplasm, it does not 
involve protein transport to the nucleus. It also provides a better control of the activation.  
There are, of course, several limitation and disadvantages, which are common to all yeast 
two-hybrids: some hybrid proteins may not be stably expressed in yeast or bacteria; fusion 
proteins may occlude the normal site of interaction or impair the proper folding; conditions in 
yeast may not allow the proper folding or posttranscriptional modifications. 
One problem that is commonly encountered with library screens is achieving optimal 
transformation efficiency. Most protocols are a variation of standard lithium acetate 
transformation protocols. After testing several of these protocols we achieved good co-
transformation efficiencies allowing us to screen approximately 3 million colonies. The 
quality of the carrier DNA and the freshness of the plated yeast streak are two critical factors 
that influence greatly the efficiency of the transformation. 
Another major problem with two-hybrid screens is the appearance of false-positive clones. In 
the classic two-hybrid system, they are inherent in any transcriptional readout. In the 
CytoTrap system, the human SOS, as an adaptor protein, will interact with a number of other 
proteins.  Any candidates from the primary screen must be retested in several configurations 
before they can be considered ‘true’ positives. First, the library plasmid must be separated 
from the bait plasmid. This is usually done by recovering the plasmid from yeast and 
transforming into bacteria, which are then grown on medium containing the same antibiotic 
for which the plasmid encoding the candidate gene contains a resistance gene. Once a 
plasmid has been recovered, it should be tested in the absence of the bait. Normally, a false 
positive will produce an interaction with the human SOS protein alone. The collagenase I 
expressed by the pSos Coll negative control plasmid can also be a useful control, as this 
protein does not generate interactions with most of the proteins.  
As we obtained quite a high number of false positives, we also considered the possibility that 
SOS would mask an interaction between the bait (CD23) and a potential target. If the 
interaction partner would be a small G protein, for example, SOS could also interact with it 
in the absence of the bait. We tested some of the clones we obtained in the screening with 
CytoTrap system in another two-hybrid, the MATCHMAKER GAL4 (Clontech), which is 
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based on the classical priciple of the transcriptional activation. This additional control proved 
them to be false positive indeed. 
In the case of our particular bait construct, a limiting factor for finding an interaction partner 
could be the size of the CD23 intracytoplasmic tail. The principle of the Cytotrap system is 
that, when bait and target interact, the SOS molecule is recruited to the membrane where it 
can activate Ras. Since CD23 is a transmembrane receptor we could only use the 
cytoplasmic domain as bait. Cloning the transmembrane region into the pSos vector would 
permanently anchor SOS to the membrane. The cytoplasmic tail of CD23 has only 21 amino 
acids for CD23a and 20 amino acids for CD23b. Nevertheless, successful screening with 
baits as small as 22 aminoacids have been previously described [50].  
Another limiting factor for a successful screening could be the big size (170 kDa) and the 
tridimensional conformation of the human SOS.  In order to partially overcome this problem 
we introduced a linker region between the bait and the hSOS in the second bait construct. 
This linker, represented by a 15 amino acids long synthetic hinge region, was designed to 
make the bait more obvious in the context of the fusion protein. 
The expression of the fusion proteins between human SOS and CD23 was assessed using an 
anti-SOS antibody, as available anti-CD23 antibodies against the cytoplasmic tail of CD23 
do not work in Western Blot. Two different bait constructs (pSosCD23a/b and 
pSosCD23a/b+Linker) were used for screening. In the first construct the cytoplasmic tail of 
CD23 was cloned into the MCS of the pSos vector, which expressed it at the C-terminal end 
of the human SOS. In the second construct the cytoplasmic tail was cloned upstream of the 
human SOS gene (with this construct we intended to create a fusion protein in which the free 
end of the bait to be the N-terminal region of CD23, as it occurs in vivo). In order to insure 
the expression of this fusion protein, we created a new START codon with a Kozak sequence 
situated upstream. Both fusion proteins were successfully expressed in the yeast cytoplasm, 
as assessed by Western Blot (Fig.22). 
The CD23 receptor is expressed as a trimer on the surface of the cells. This could also raise 
potential problems since the fusion protein expresses only one copy of the CD23 cytoplasmic 
domain. A previous study involving chimeric proteins between the CD23 and CD69 
molecules indicate that this is not the case [68]. Monomeric chimeras containing the 
cytoplasmic domain of CD23 fused with the extracellular domain of CD69 could efficiently 
transduce signals into the cell and provoke Ca2+ mobilization. The described chimeras 
demonstrated the modular nature of the molecule, with the ligand-binding and signal 
transduction domains independent of each other. The experiment also confirmed that the 
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cytoplasmic domain is fully responsible for signal transduction. On the other hand, 
oligomerization seems to be quite an important factor for ligand binding. CD23 affinity for 
IgE decreases in monomeric CD23 or in the case of small soluble CD23 fragments, which 
don’t retain the helical coiled coil [38]. 
Another way in which a two-hybrid system can be used is to test an interaction between two 
known proteins. The analysis of the amino acid sequence in the cytoplasmic tail of CD23 and 
previous experiments pointed out several potential targets for this membrane receptor. As 
mentioned already, the product of a transfected CD23 gene in a NK cell line was found 
associated with fyn, a member of the src-family of protein kinases [78]. Also, if the tyrosine 
residue in the CD23a isoform is part of a functional ITIM motif, phosphatases like SHP and 
SHIP could be recuited through their SH2 domains. The gene for fyn has been cloned as 
cDNA into the pMyr vector and the ability to interact with CD23a and CD23b was tested in 
the system. Similar experiments were performed for SHP-1 and SHP-2 (results not shown). 
Anyway, as all these interaction would normally involve the phosphorylation of the tyrosine 
residue, yeast two-hybrid may not be the appropriate system to assess them. Yeast hosts 
might not express the kinases or they might not have the same phosphorylation patterns as 
the mammalian kinases. To overcome this problem one can, for example, express the 
required kinases in the yeast cytoplasm. 
Another approach to overcome this problem would be to replace the tyrosine residue with a 
glutamic acid residue. This strategy can be used in experimental settings when tyrosine 
phosphorylation cannot be achieved. By site directed mutagenesis, we constructed a new bait 
vector, named pSosCD23a-Glu, in which the tyrosine from position 6 of the cytoplasmic tail 
of CD23a was replaced with a glutamic acid residue. We used this new construct in order to 
test the interaction between CD23a and fyn, SHP-1 and SHP-2. With this construct also no 
interaction was found. We also plan to use this new bait construct for future screening of the 
spleen library. 
In conclusion, we used a yeast two-hybrid system in order to identify a direct interaction 
partner for CD23. This involved first the direct testing of interactions between the bait and 
possible or predicted interaction partners and secondly the intensive screening of a spleen 
library using different bait constructs. Other experimental approaches – like 
immunoprecipitation assays- were also tested (results not shown). These strategies did not 
result in the identification of an interaction partner for CD23 up to now.  
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To summarize, we demonstrate that Pax-5 regulates the CD23a promoter, proving to be a 
key regulator of B-cell specific expression of CD23a isoform. The establishment of a two-
hybrid system represents a solid base for future investigations of the signaling mechanisms 
through the CD23 receptor.  
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ABSTRACT 
 
 
 
 
Two isoforms of human CD23 (CD23a and CD23b) have been described. They differ by 
only 6-7 residues in the N-terminal cytoplasmic tail. CD23a is restrictively expressed on B-
cells while CD23b is inducible on B-cells, as well as monocytes, eosinophils, macrophages 
and a variety of other cell types, after IL-4 stimulation. 
The two isoforms seems to have different functions. CD23a appears to be the isoform 
associated with endocytosis of IgE immune complexes and mediating antigen presentation on 
B-cells. CD23b has a phagocytosis motif and seems to be involved in the phagocytosis of 
IgE-coated particles, cytokine release and the generation of superoxides. 
Previous studies indicate that the two isoforms connect to different signal transduction 
pathways. Comparing the cells that express only one or both CD23 isoforms suggests that 
CD23b is involved in upregulating cAMP and iNOS, whereas CD23a mediates an increase in 
intracellular calcium.  
In the main part of the study we investigated how the CD23a B-cell specific expression is 
regulated. Pax-5 is a B-cell restricted transcription factor with an essential role in early and 
late B-cell development. Putative Pax-5 binding sites have been predicted in the CD23a 
proximal promoter. Analyses of the CD23a promoter revealed three putative Pax-5 binding 
sites with more than 50% homology to the consensus sequence. One of these sites, named 
CD23-1 can compete a high affinity Pax-5 binding site or can directly bind Pax-5 protein in 
electrophoretic mobility shift assays. Introducing mutations into this site abrogates the 
binding. A different approach, in which overlapping peptides covering the length of the 
CD23a promoter were tested in competition assays against a high affinity binding site, also 
revealed CD23-1 as the only site that directly binds Pax-5 protein. 
Expression of Pax-5 in 293 cells resulted in a 7-fold activation of a CD23a core promoter 
construct. Co-transfection together with STAT6 showed that Pax-5 cooperates with this 
transcription factor in enhancing the level of transcription of a CD23a extended promoter 
construct. Most importantly, ectopic expression of Pax-5 in the monocytic cell line U-937 
that regularly expresses only the CD23b isoform enabled a significant CD23a expression 
after stimulation with IL-4 and PMA.  
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Our results suggest that Pax-5 is a key regulator of the B-cell restricted expression of the 
CD23a isoform. 
In the second part of the project, we used a yeast two-hybrid system (CytoTrapTM from 
Stratagene) in order to look for cytoplasmic interaction partners for the CD23 receptor. The 
system was established in order to reach a high efficiency of transformation and different bait 
vector constructs were made. The screening was performed using a human spleen library 
cloned in the target vector of the system. The first bait constructs used (pSosCD23a and 
pSosCD23b) expressed the very short (22 amino acids) cytoplasmic tails of the isoforms at 
the C-terminal end of the fusion protein (human SOS). Improved bait constructs, 
(pSosCD23a+Linker and pSos CD23b+Linker) expressed the cytoplasmic tail of CD23a/b at 
the N-terminal side of the human SOS and had in consequence the N-terminal part free as a 
bait, as it occurs in vivo. A flexible linker region separated the fusion proteins in order to 
make the small amino acid bait chain more obvious. Approximately three million library 
clones were screened with these various constructs. No “true positive” interaction was 
detected. A relatively high number of “false positive” clones were obtained and checked in 
another two-hybrid system. A new bait construct, in which the tyrosine residue in the 
cytoplasmic tail of CD23a was replaced by a glutamic acid residue will be used for future 
screening. 
The system was also used in order to test the interaction between CD23 and p59fyn, a 
member of the Src family of protein kinases that was mentioned to associate with CD23a. No 
interaction was detected by using the CytoTrap two-hybrid system. 
In conclusion, the key result of the study demonstrates that Pax-5 is a main regulator of the 
B-cell specific expression of the CD23a isoform. In addition, a two-hybrid system was 
established and employed in order to look for cytoplasmic interaction partners for CD23.  
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ZUSAMMENFASSUNG 
 
 
 
Bisher sind zwei Isoformen des humanen CD23 (CD23a und CD23b) beschrieben. Beide 
unterscheiden sich lediglich in 6-7 Resten im N-terminalen, zytoplasmatischen Anteil. 
CD23a wird ausschließlich auf B-Zellen exprimiert, während CD23b sowohl auf B-Zellen als 
auch auf Monozyten, eosinophilen Granulozyten, Makrophagen und zahlreichen anderen 
Zelltypen durch Stimulation mit IL-4 induziert werden kann.  
Die beiden Isoformen vermitteln wahrscheinlich unterschiedliche Funktionen. CD23a gilt als 
Isoform, welche vornehmlich mit der Endozytose von IgE-Immunkomplexen und der 
Vermittlung von Antigen-Präsentation auf B-Zellen assoziiert ist. CD23b besitzt ein 
Phagozytose-Motiv und scheint bei der Phagozytose IgE besetzter Partikel, der Freisetzung 
von Zytokinen und der Bildung von Peroxiden eine Rolle zu spielen. 
Frühere Untersuchungen legen die Vermutung nahe, dass die beiden Isoformen zwei 
getrennte Signalübertragungswege miteinander verbinden. Die Gegenüberstellung von 
Ereignissen, welche in Zellen, die nur eine einer oder beide Isoformen von CD23 besitzen, 
stattfinden, legt die Vermutung nahe, dass CD23b cAMP und iNOS hochreguliert, 
wohingegen CD23a einen Anstieg des intrazellulären Kalziums vermittelt.  
Im ersten Teil unserer Untersuchungen haben wir die Regulation der B-Zell-spezifischen 
Expression von CD23a analysiert. Pax-5 ist ein auf B-Zellen beschränkter 
Transkriptionsfaktor, welcher für die frühe und späte B-Zellentwicklung von entscheidender 
Bedeutung ist. Mögliche Pax-5 Bindungsstellen wurden in den proximalen Abschnitten des 
CD23a Promotors vermutet. Die Analyse des CD23a Promotors ergab drei mutmaßliche Pax-
5 Bindungsstellen mit mehr als 50% Homologie zur Konsensus-Sequenz. Eine dieser 
Bindungsstellen, namens CD23-1, kann mit einer hochaffinen Pax-5 Bindungsstelle 
konkurrieren oder direkt das Pax-5 Protein in Elektromobilitäts Experimenten (EMSA) 
binden. Das Einfügen von Mutationen an dieser Stelle verhindert die Bindung. Ein weiterer 
Versuch, bei dem die gesamte Länge des CD23a Promotors durch überlappende Peptide in 
einem kompetitiven Verfahren gegenüber hoch affinen Bindungsstellen getestet wurde, zeigt 
ebenso CD23-1 als die einzige Stelle, welche direkt Pax-5 binden kann. 
In weiteren Experimenten führte die Expression von Pax-5 in 293 Zellen zu einer 7fachen 
Aktivierung  eines CD23a Kernpromotor Konstrukts. Die Kotransfektion zusammen mit 
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STAT6 zeigte, dass Pax-5 mit diesem Transkriptionsfaktor kooperiert, indem es die 
Transkriptionsrate eines vergrößerten CD23a Promotorkonstrukts erhöht. Von besonderer 
Bedeutung ist die Tatsache, dass die ektope Expression von Pax-5 in der monozytären 
Zelllinie U-937, die normalerweise nur die CD23b Isoform exprimiert, dann zu einer 
Expression von CD23a nach Stimulation mit IL-4 und PMA führte. Unsere Ergebnisse legen 
nahe, dass Pax-5 in der auf B-Zellen beschränkten Expression der CD23 Isoform eine 
Schlüsselrolle zukommt.  
Im zweiten Teil des Projekts haben wir ein “Zwei-Hefen-Hybrid-System“  (Cyto-Trap von 
Stratagene) verwendet, um nach zytoplasmatischen Interaktionspartnern für den CD23 
Rezeptor zu suchen. Das System wurde modifiziert um eine hohe Effizienz an 
Transformation zu erzielen. Unterschiedliche „Köder“-Vektorkonstrukte wurden hergestellt. 
Das Screening wurde mittels einer humanen Milzbibliothek mit dem Zielvektor des Systems 
durchgeführt. Die anfangs benutzten Konstrukte –pSosCD23a und pSosCD23b – 
exprimierten sehr kurze (22 Aminosäuren) zytoplasmatischen Reste der Isoformen am C-
terminalen Ende des Fusionsproteins (humanes SOS). Verbesserte Konstrukte (pSos 
CD23a+Linker und pSosCD23b+Linker) exprimierten den zytoplasmatischen Anteil von 
CD23a/b am N-terminalen Ende des humanen SOS und hatten folglich den N-terminalen 
Anteil als Andockstelle frei, entsprechend den Bedingungen in vivo. Eine flexible 
Verbindungsregion trennte die Fusionsproteine, um auf diese Weise die kurze 
Aminosäurekette deutlich „sichtbar“ werden zu lassen. Annähernd drei Millionen Klone 
wurden mittels der verschiedenen Konstrukte untersucht. Dabei konnte keine tatsächlich 
positive Interaktion gefunden werden. Stattdessen fand sich eine vergleichsweise hohe Zahl 
falsch-positiver Klone. Diese wiederum wurden in einem zweiten “Zwei-Hefen-Hybrid-
System“ getestet. 
In Zukunft wird ein neues Konstrukt als Köder verwendet werden. Hierbei wurde ein 
Tyrosin-Rest im zytoplasmatischen Anteil von CD23a durch Glutamat ersetzt. Das System 
wurde bereits dazu verwendet, die Interaktion zwischen CD23 und p59fyn - einem Mitglied 
der Src-Familie von Proteinkinasen, welches mit CD23a assoziiert sein soll – zu testen. 
Jedoch konnte im CytoTrap “Zwei-Hefen-Hybrid-System“ keine Wechselwirkung 
nachgewiesen werden. 
Zusammenfassend zeigt das zentrale Ergebnis der Arbeit, dass Pax-5 der Schlüsselregulator 
ist, der die B-Zell-spezifische Expression von CD23a ermöglicht. Zusätzlich wurde ein 
“Zwei-Hefen-Hybrid-System“ etabliert, mit dem zytoplasmatische Interaktionspartner für die 
CD23 Isoformen gefunden werden können.  
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ABREVIATIONS 
 
 
 
A260      absorbance at 260 nm 
aa      amino acids     
AD       activation domain 
Ag       antigen 
B-CLL      chronic lymphocytic leukemia 
BCR      B cell receptor 
BLNK      B cell Linker  
BSA          bovine serum albumine 
BSAP      B-cell-specific activator protein 
bp       base pairs 
3’C∝      immunoglobulin heavy-chain enhancer  
Ca2+      calcium 
cAMP       adenosine 3’,5’-cyclic-monophosphate 
CBF1       C promoter binding factor 1 
C/EBP      CCAAT/ enhancer binding protein 
CD      cluster of differentiation 
CD40L     CD40 ligand 
cDNA      complementary DNA 
CIP       calf intestinal phosphatase 
cpm       counts per minute 
CR2/CR3/CR4    complement receptor 2/3/4 
CRE      cAMP response element 
CREB      cAMP response element binding protein 
CY      cytoplasmic domain 
Cε       immunoglobulin ε chain constant region exon 
Cγ1      immunoglobulin γ1 chain constant region exon 
DAG      diacylglycerol 
dCTP       deoxycytidine triphosphate 
DMEM     Dulbeccos minimum essential medium 
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DNA       deoxyribonucleic acid 
DNA-BD      DNA-binding domain 
dNTP       deooxynucleoside triphosphate 
d(TGA)TP      deoxy(thymidine/guanosine/adenosine/) 
 triphosphate 
DTT       dithiothreinol 
EBF       early B-cell factor 
EBNA-2     Epstein-Barr virus nuclear antigen-2   
EBV       Epstein-Barr virus 
EC      extracellular domain 
EDTA      ethylenediaminetetraacetic acid 
EMSA      Electrophoretic Mobility Shift Assay 
Erk      extracellular-regulated kinase  
Eµ      Ig heavy chain intronic enhancer 
FACS       fluorescence-activated cell sorter 
FCS      fetal calf serum 
FcεRI      high affinity IgE receptor 
FcεRII      CD23, low affinity IgE receptor 
Fwr       forward primer 
Gal(-Ura,-Leu)    galactose medium without uracil and leucine 
GDP      guanosine 5’-diphosphate 
Glu      glutamic acid 
Glu(-Ura,-Leu)    glucose medium without uracil and leucine 
GTP      guanosine 5’-triphosphate  
H2A-2/ H2B-2    histone genes 
HA       hemagglutinin 
HEPES N-2-hydroxyethylpiperazine-N’-2-    
ethanesulfonic acid  
3’α-hs4 DNase hypersensitivity site 4 in the α gene 
enhancer 
HSC      hematopoietic stem cell 
hSOS       human SOS 
IC       immune complexes 
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IFN-α      interferon-α 
IFN-γ      interferon-γ  
IgA/ IgD/ IgE/ IgG/ IgM    immunoglobulin A / D / E / G / M 
Ikkα/β      inhibitor of NF-kB kinase α/β  
IkB      inhibitor of NF-kB 
IL-1/ IL-4/ IL-6    interleukins 
Ile      isoleucine 
INOS      inducible nitric oxide synthase 
IP3      inositol 1,4,5-triphosphate 
JAK      Janus Kinase 
ITAM immunoreceptor tyrosine based activation 
motifs 
ITIM immunoreceptor tyrosine based inhibitory 
motifs 
LB       luria broth 
Leu      leucine 
LFA-1      lymphocyte-function-associated antigen-1 
LiAc       lithium acetate 
LPS      lipopolysaccharide 
MAPK      mitogen-activated protein kinase 
MCS      multiple cloning site  
M-CSF-R      macrophage colony-stimulating factor receptor 
Met       methionine 
MHC      major histocompatibility complex 
mRNA      messenger RNA 
N (nucleotide)     any nucleotide 
NF-AT     nuclear factor of activated T cells   
NK      natural killer cells 
NOS      nitric oxide synthase 
OD       optical density 
Oct-1      octamer binding protein-1 
PAGE       Polyacrylamide Gel Electrophoresis  
PBS      phosphate-buffered saline 
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PCR       polymerase chain reaction 
PEG       polyethylene glycol 
PIP2      phosphatidylinositol biphosphate 
PKA      protein kinase A 
PKC      protein kinase C 
PLC /PLC-γ     phospholipase C-γ 
PMA       phorbolemyristatacetate 
PMSF       phynilmethylsulfonyl fluoride 
poly[d(I-C)]     poly-deoxy-inosinic-deoxy-cytidylic acid  
R (nucleotide)     A or G 
RAG-2     recombination-activating genes-2    
RGD      arginine-glutamine-aspartic acid 
rIL-4      recombinant IL-4 
RNA       ribonucleic acid 
RNase      ribonuclease 
RPA       RNase protection assay 
rpm       rotations per minute 
RPMI  
RT-PCR      reverse-transcriptase polymerase chain reaction 
S (nucleotide)     C or G 
Sγ2a  switch region for immunoglobulin γ2a chain 
constant region 
Sµ switch region for immunoglobulin µ chain   
constant region 
Ser      serine 
sCD23      soluble CD23   
SDS      sodium dodecyl sulphate 
SH2      Src homology domain 2 
SH3      Src homology domain 3 
SHP-1 SH2-domain-containing protein tyrosine  
phosphatase 1 
SHP-2 SH2-domain-containing protein tyrosine 
phosphatase 1 
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SHIP SH2-domain-containing inositol polyphosphate 
5’ phosphatase 
SOS      Son of Sevenless     
Src/ src     Rous sarcoma 
STAT6     signal transducer and activator of transcription 
SV40      simian virus 40 
TAE      Tris acetate electrophoresis buffer 
TBE      Tris borate electrophoresis buffer 
TEMED      N,N,N’,N’-tetramethylethylenediamine 
TM      transmembrane domain 
TNF      tumor necrosis factor 
Tris       tris(hydroxymethyl)aminomethane 
TSAP      tissue specific activator protein 
Tyr      tyrosine 
UAS       upstream activatory sequence 
Ura       uracil 
UTP      uridine-5’-triphosphate  
XBP-1      X-box-binding protein 1 
Y (nucleotide)     C or T 
YPAD      Yeast extract, Peptone, Dextrose medium 
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